[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2931
1. Li Y, Schnekenburger J, Duits MH: Intracellular particle tracking as a tool for tumor cell characterization. J Biomed Opt; 2009 Nov-Dec;14(6):064005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the dynamics of two types of intracellular probe particles, ballistically injected latex spheres and endogenous granules, in tumor cell lines of different metastatic potential: breast tumor cells (MCF-7 malignant, MCF-10A benign) and pancreas adenocarcinoma (PaTu8988T malignant, PaTu8988S benign).
  • Mechanical analysis of the same cell lines with atomic force microscopy (AFM) in force-distance mode revealed that AFM could distinguish between the benign and malignant breast cancer cells but not the pancreatic tumor cell lines.
  • [MeSH-minor] Breast Neoplasms / ultrastructure. Cell Line, Tumor. Female. Humans. Intracellular Space. Microspheres. Pancreatic Neoplasms / ultrastructure. Particle Size

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059243.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Jung JY, Song MH, Park YS, Jo YJ, Kim SH, Jun DW, Kim DH, Lee WM: [A case of mucinous noncystic carcinoma of the pancreas]. Korean J Gastroenterol; 2008 Mar;51(3):204-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a well-defined entity in breast or large bowel.
  • In the past, MNCC generally had been categorized together with ordinary ductal adenocarcinoma or misdiagnosed as mucinous cystadenocarcinoma or signet-ring cell carcinoma.
  • The new WHO classification lists MNCC as a variant of ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451696.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP: Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res; 2006 Nov 15;66(22):10647-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers.
  • Estrogen exposure is considered a significant risk factor for breast cancer development.
  • Estrogen receptor (ER) alpha is expressed at low levels in normal epithelia, and its expression is dramatically up-regulated as transformation progresses during mammary hyperplasia and adenocarcinoma development.
  • Interestingly, Cav-1 dominant-negative mutations are exclusively found in ERalpha-positive breast cancer samples.
  • [MeSH-major] Adult Stem Cells / pathology. Breast Neoplasms / genetics. Caveolin 1 / genetics. Mammary Glands, Animal / pathology. Mammary Glands, Human / pathology. Neoplasms, Hormone-Dependent / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108100.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA80250; United States / NCI NIH HHS / CA / R01CA93596; United States / NCI NIH HHS / CA / R01CA98779
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / Estrogen Receptor alpha
  • [Number-of-references] 41
  •  go-up   go-down


Advertisement
4. Peteiro A, Duarte AM, Honavar M: Breast carcinoma metastatic to follicular adenoma of the thyroid gland. Histopathology; 2005 May;46(5):587-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma metastatic to follicular adenoma of the thyroid gland.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Breast Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842643.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


5. Martín-Ondarza C, Gil-Moreno A, Torres-Cuesta L, García A, Eyzaguirre F, Díaz-Feijoo B, Xercavins J: Endometrial cancer in polyps: a clinical study of 27 cases. Eur J Gynaecol Oncol; 2005;26(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three breast cancer patients were currently given tamoxifen.
  • Metrorrhagia was the presenting symptom in 74% of cases, although 22% of patients were asymptomatic at the time of diagnosis.
  • Diagnosis was made by aspiration-biopsy in 13 patients and by hysteroscopic endometrial sampling in 13 (in one patient endometrial carcinoma was incidentally found in the surgical specimen).
  • [MeSH-minor] Adenocarcinoma, Papillary / epidemiology. Adenocarcinoma, Papillary / etiology. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / ultrasonography. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / etiology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / ultrasonography. Carcinoma, Endometrioid / epidemiology. Carcinoma, Endometrioid / etiology. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / ultrasonography. Female. Humans. Medical Records. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Spain / epidemiology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755002.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Pinto-Correia AL, Sousa H, Fragoso M, Moreira-Dias L, Lopes C, Medeiros R, Dinis-Ribeiro M: Gastric cancer in a Caucasian population: role of pepsinogen C genetic variants. World J Gastroenterol; 2006 Aug 21;12(31):5033-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Our results revealed that Allele 6 carriers seemed to have protection against the development of any gastric lesion (OR = 0.34; P<0.001), non-dysplastic lesions associated with gastric adenocarcinoma such as atrophy or intestinal metaplasia (OR = 0.28; P<0.001) or invasive GC (OR = 0.39; P = 0.004).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Gene. 2004 Oct 27;341:1-17 [15474284.001]
  • [Cites] Jpn J Cancer Res. 1989 Feb;80(2):111-4 [2498245.001]
  • [Cites] Trends Genet. 1989 Dec;5(12):391 [2623762.001]
  • [Cites] Adv Exp Med Biol. 1991;306:95-9 [1812765.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Eur J Cancer Prev. 1995 Oct;4(5):389-417 [7496328.001]
  • [Cites] Ann Hum Genet. 1997 Mar;61(Pt 2):93-7 [9177116.001]
  • [Cites] Eur J Cancer. 1997 Jun;33(7):1075-107 [9376190.001]
  • [Cites] Gut. 1997 Oct;41(4):469-74 [9391244.001]
  • [Cites] Hum Genet. 1997 Dec;101(2):201-4 [9402969.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):449-56 [15548353.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] World J Gastroenterol. 2005 May 7;11(17):2545-8 [15849808.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jul 1;160(1):49-54 [15949570.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 26;334(2):588-92 [16009345.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):256-62 [16364249.001]
  • [Cites] Eur J Cancer Prev. 2006 Aug;15(4):362-6 [16835507.001]
  • [Cites] Breast J. 2002 Jul-Aug;8(4):226-9 [12100115.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11(4):343-50 [12195160.001]
  • [Cites] World J Gastroenterol. 2003 Jan;9(1):50-3 [12508350.001]
  • [Cites] Cell Physiol Biochem. 2003;13(5):301-8 [14586174.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2507-20 [14602137.001]
  • [Cites] Prostate. 2004 May 15;59(3):268-74 [15042602.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):116-21 [15066318.001]
  • [Cites] Eur J Cancer Prev. 2004 Jun;13(3):177-81 [15167216.001]
  • [Cites] Angiogenesis. 2004;7(1):53-8 [15302996.001]
  • [Cites] Nucleic Acids Res. 1988 Oct 11;16(19):9372 [2902599.001]
  • (PMID = 16937501.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 61536-72-9 / Pepsinogen C; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC4087408
  •  go-up   go-down


7. Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML: Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin Cancer Res; 2008 Dec 1;14(23):7947-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients had partial responses (gastric adenocarcinoma and heavily pretreated breast cancer).
  • Preliminary clinical activity was observed in breast and gastric cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047127.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid; 0 / Glutarates; 0 / Isoindoles; 0 / Quinazolines; 0LVT1QZ0BA / Homocysteine; EC 2.1.1.45 / Thymidylate Synthase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Brück P, Vilches Cisneros N, Ramos López E, Barboza Quintana O, Ancer Rodríguez J, Flores Gutiérrez JP: [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients]. Ginecol Obstet Mex; 2006 Oct;74(10):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
  • [Transliterated title] Expresión del Her2-Neu en el adenocarcinoma ductal de la glándula mamaria: correlación con parámetros histopatológicos y expresión de receptores estrogénicos en pacientes mexicanas.
  • BACKGROUND: Breast cancer is a general health problem that annually produces 400,000 deaths worldwide.
  • Its early diagnosis leads to high cure rates; nevertheless, in Mexico City this happens rarely.
  • Her2-Neu is an oncogene that is expressed on breast cancer cells, with aggressive behaviour and metastasis.
  • OBJECTIVE: To know the biology and distribution of Her2-Neu expression in Mexican breast cancer patients in order to evaluate its potential as a prognostic and predictive factor in the treatment of the breast cancer.
  • PATIENTS AND METHOD: In the cases of invasive ductal adenocarcinomas of the breast we compared by immunohistochemistry the Her2-Neu and estrogen receptor expressions with the histopathological characteristics.
  • RESULTS: We found 122 cases of breast adenocarcinoma, from which we evaluated 108 for fulfilling the selection criteria of invasive ductal adenocarcinoma.
  • CONCLUSIONS: Since the percentage of patients with Her2-Neu expression is high (36.1%) and there is a close relation between Her2-Neu expression, the tumour size and the presence of lymph node methastasis, the determination of the oncoprotein expression could allow a more detailed prognosis and the treatment with immunotherapy and anthracyclines in order to influence the course of the breast cancer cases.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Genes, erbB-2. Neoplasm Proteins / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21961357.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


9. Bassarova AV, Nesland JM, Davidson B: D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol; 2006 Jul;30(7):878-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another challenging issue especially in the field of serous effusions is the differential diagnosis between malignant mesothelioma and metastatic adenocarcinoma.
  • The aim of this study was to evaluate the potential use of the D2-40 antibody detecting the M2A oncofetal antigen in the diagnosis of malignant serous effusions.
  • Two hundred and ninety effusion specimens (169 ovarian carcinomas, 44 breast carcinomas, 32 malignant mesotheliomas, 6 lung carcinomas, 8 reactive specimens, and 31 tumors of other origin) were assessed.
  • Positive membranous staining was observed in 58% of ovarian carcinomas, 33% of lung carcinomas, and 30% of breast carcinomas.
  • Pulmonary, breast, and nonovarian gynecologic tumors usually showed weak focal membranous staining, whereas the ovarian adenocarcinomas showed an expression pattern more similar to mesotheliomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Mesothelioma / metabolism. Mesothelioma / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819331.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


10. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer; 2006 Mar;13(1):7-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone metastases are common in patients with many types of cancer, especially breast and prostate cancer--in which the incidence is approximately 70% among patients with advanced metastatic disease.
  • Aminobisphosphonates (NBPs) have entered clinical practice in the treatment of bone metastases from several neoplasms, including breast and prostate adenocarcinoma, as a result of their anti-resorption properties.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601276.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphosphonates
  • [Number-of-references] 143
  •  go-up   go-down


11. Javid SH, Smith BL, Mayer E, Bellon J, Murphy CD, Lipsitz S, Golshan M: Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg; 2009 May;197(5):674-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast: results of a large contemporary series.
  • BACKGROUND: Tubular carcinoma (TC) of the breast is an uncommon subtype associated with a favorable prognosis.
  • METHODS: We performed a retrospective review of cases of TC of the breast treated between 1997 and 2004.
  • RESULTS: We identified 111 cases of TC of the breast.
  • The median patient age at diagnosis was 55 years, and the median follow-up period was 72 months.
  • Breast-conservation surgery was performed in 75% (83 of 111) of patients.
  • One patient developed an in-breast recurrence.
  • No patient developed distant metastases or died from breast cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy, Segmental

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789411.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Sakurai N, Nakagawa-Goto K, Ito J, Sakurai Y, Nakanishi Y, Bastow KF, Cragg G, Lee KH: Cytotoxic Alangium alkaloids from Alangium longiflorum. Phytochemistry; 2006 May;67(9):894-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biological evaluation showed that 2, 10-O-demethylcephaeline, exhibited potent cytotoxic activity against human lung carcinoma (A549) and breast adenocarcinoma (MCF-7) with ED(50) values of 0.013 and 0.062 microM, respectively.
  • [MeSH-minor] Breast Neoplasms / drug therapy. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Lung Neoplasms / drug therapy. Molecular Structure. Plant Bark / chemistry. Stereoisomerism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530796.001).
  • [ISSN] 0031-9422
  • [Journal-full-title] Phytochemistry
  • [ISO-abbreviation] Phytochemistry
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-17625
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 10-O-demethylcephaeline; 0 / Alkaloids; 0 / Terpenes; 0 / Tetrahydroisoquinolines; 0 / isocephaeline
  •  go-up   go-down


13. Song SH, Lee JK, Saw HS, Choi SY, Koo BH, Kim A, Yeom BW, Kim I: Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures. J Korean Med Sci; 2006 Aug;21(4):752-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures.
  • Her previous medical history was PJS and breast cancer.
  • An ovarian sex cord tumor with annular tubules was incidentally diagnosed together with a minimal deviation adenocarcinoma of the uterine cervix and mucinous metaplasia of both the Fallopian tubal mucosa and the endometrium.
  • Although the cases of multiple genital tract tumors with PJS has rarely been reported, the present case appears to be the first in Korea in which the PJS syndrome was complicated by multiple genital tract tumors and infiltrating carcinoma of the breast.
  • The clinical significance of the multiple genital tract tumors and breast cancer associated with PJS is reviewed.
  • [MeSH-major] Breast Neoplasms / pathology. Ovarian Neoplasms / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Carcinoma, Ductal, Breast / complications. Carcinoma, Ductal, Breast / pathology. Endometrium / pathology. Fallopian Tubes / pathology. Female. Humans. Korea. Metaplasia. Sex Cord-Gonadal Stromal Tumors / complications. Sex Cord-Gonadal Stromal Tumors / pathology


14. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP: Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med; 2009;7:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Endometrial Neoplasms / metabolism. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):61-70 [11518467.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):405-13 [19153755.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Radiology. 2002 May;223(2):410-6 [11997546.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] J Histochem Cytochem. 2003 Oct;51(10):1291-7 [14500697.001]
  • [Cites] Curr Treat Options Oncol. 2004 Apr;5(2):119-27 [14990206.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):862-6 [8302707.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):41-7 [7817943.001]
  • [Cites] Nat Genet. 1995 May;10(1):114-6 [7647780.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):61-5 [9495360.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):23-8 [10071231.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1497-504 [16224217.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):1026-30 [16831029.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1310-6 [16799478.001]
  • [Cites] Clinics (Sao Paulo). 2006 Oct;61(5):417-24 [17072439.001]
  • [Cites] Actas Urol Esp. 2006 Sep;30(8):754-62 [17078572.001]
  • [Cites] Ann Surg Oncol. 2006 Dec;13(12):1633-44 [17013685.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):306-13 [17242700.001]
  • [Cites] J Negat Results Biomed. 2007;6:6 [17459164.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10686-93 [18006810.001]
  • [Cites] J Transl Med. 2007;5:54 [17971233.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):402-23 [18318583.001]
  • [Cites] J Transl Med. 2008;6:31 [18559092.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:25 [18673574.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • (PMID = 19366452.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  • [Other-IDs] NLM/ PMC2672079
  •  go-up   go-down


15. Al-Wadei HA, Schuller HM: Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas. J Pathol; 2009 Aug;218(4):437-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nicotinic receptor-associated modulation of stimulatory and inhibitory neurotransmitters in NNK-induced adenocarcinoma of the lungs and pancreas.
  • Small airway-derived pulmonary adenocarcinoma (PAC) and pancreatic ductal adenocarcinoma (PDAC) are among the most common human cancers and smoking is a risk factor for both.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):294-9 [15900604.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):639-48 [16091975.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):431-5 [16391865.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):618-28 [16269536.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1370-80 [16206275.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Cancer Biol Ther. 2006 May;5(5):511-7 [16582591.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1547-52 [16671086.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):403-11 [17067750.001]
  • [Cites] Toxicol Sci. 2007 Mar;96(1):21-9 [17003101.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):261-7 [17498763.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6863-71 [17638897.001]
  • [Cites] Cancer Genomics Proteomics. 2007 Jan-Feb;4(1):35-42 [17726239.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1737-44 [17557921.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2002 Mar;29(3):181-8 [11906480.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] J Neurobiol. 2002 Dec;53(4):606-17 [12436424.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6467-9 [12438237.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;978:405-12 [12582069.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):63-70 [12889599.001]
  • [Cites] Prog Cardiovasc Dis. 2003 Jul-Aug;46(1):91-111 [12920702.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):11-8 [15196729.001]
  • [Cites] Neurosci Lett. 2004 Nov 3;370(1):80-3 [15489022.001]
  • [Cites] Biochem Pharmacol. 1989 Oct 15;38(20):3439-42 [2573356.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1960-5 [2306745.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3294-8 [2159143.001]
  • [Cites] Mutat Res. 1990 Nov-Dec;233(1-2):105-16 [2233792.001]
  • [Cites] Neuron. 1991 Jul;7(1):91-100 [2069816.001]
  • [Cites] IARC Sci Publ. 1991;(105):54-61 [1855913.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):767-78 [18098271.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3746-53 [18559592.001]
  • [Cites] Anticancer Drugs. 2008 Aug;19(7):655-71 [18594207.001]
  • [Cites] Br J Pharmacol. 2008 Aug;154(8):1558-71 [18500366.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):345-56 [18693168.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3159-68 [18640919.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1979-85 [18310090.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):473-9 [11238189.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2866-9 [11306460.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1367-78 [11579145.001]
  • [Cites] Neurosci Lett. 2001 Oct 26;312(3):161-4 [11602335.001]
  • [Cites] Carcinogenesis. 1993 Mar;14(3):451-5 [8453721.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2498-501 [8495411.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3504-8 [7627955.001]
  • [Cites] Crit Rev Toxicol. 1996;26(2):163-81 [8688159.001]
  • [Cites] Prog Brain Res. 1996;109:125-37 [9009699.001]
  • [Cites] Cardiovasc Drugs Ther. 1997 Jan;10(6):657-65 [9110108.001]
  • [Cites] Prog Neurobiol. 1997 Oct;53(2):199-237 [9364611.001]
  • [Cites] Biochem Pharmacol. 1998 May 1;55(9):1377-84 [10076528.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Dig Dis Sci. 1999 Jul;44(7):1303-11 [10489910.001]
  • (PMID = 19274673.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA042829; United States / NCI NIH HHS / CA / R01 CA096128; United States / NCI NIH HHS / CA / R01CA042829; United States / NCI NIH HHS / CA / R01CA096128
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurotransmitter Agents; 0 / Nitrosamines; 0 / Receptors, Nicotinic; 56-12-2 / gamma-Aminobutyric Acid; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; E0399OZS9N / Cyclic AMP; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  • [Other-IDs] NLM/ NIHMS380611; NLM/ PMC3372983
  •  go-up   go-down


16. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T: Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway. J Pharmacol Sci; 2007 Jan;103(1):56-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reported that oridonin, a diterpenoid isolated from the plant Rabdosia rubescens, had apoptosis-inducing activities in many cell lines (e.g., human melanoma A375-S2, human cervical cancer HeLa, human breast adenocarcinoma MCF-7, and murine fibrosarcoma L929).

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17251686.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Diterpenes; 0 / Diterpenes, Kaurane; 0 / GRB2 Adaptor Protein; 0 / GRB2 protein, human; 0APJ98UCLQ / oridonin; 62229-50-9 / Epidermal Growth Factor; DH2M523P0H / Genistein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


17. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


18. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


19. Sohn KJ, Jang H, Campan M, Weisenberger DJ, Dickhout J, Wang YC, Cho RC, Yates Z, Lucock M, Chiang EP, Austin RC, Choi SW, Laird PW, Kim YI: The methylenetetrahydrofolate reductase C677T mutation induces cell-specific changes in genomic DNA methylation and uracil misincorporation: a possible molecular basis for the site-specific cancer risk modification. Int J Cancer; 2009 May 1;124(9):1999-2005
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is associated with a decreased risk of colon cancer although it may increase the risk of breast cancer.
  • We investigated the effect of this mutation on DNA methylation and uracil misincorporation and its interaction with exogenous folate in further modulating these biomarkers of one-carbon transfer reactions in an in vitro model of the MTHFR 677T mutation in HCT116 colon and MDA-MB-435 breast adenocarcinoma cells.
  • Our data demonstrate for the first time a functional consequence of changes in intracellular folate cofactors resulting from the MTHFR 677T mutation in cells derived from the target organs of interest, thus providing a plausible cellular mechanism that may partly explain the site-specific modification of colon and breast cancer risks associated with the MTHFR C677T mutation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Clin Genet. 2006 Apr;69(4):327-36 [16630166.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] J Nutr. 2006 Jun;136(6):1522-7 [16702315.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1005-16 [16933051.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 15;98(22):1607-22 [17105984.001]
  • [Cites] Mol Cell Biochem. 2007 Jan;294(1-2):181-7 [16855792.001]
  • [Cites] J Nutr. 2007 Mar;137(3):607-13 [17311948.001]
  • [Cites] Leukemia. 2007 Apr;21(4):651-8 [17301815.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):492-502 [17768394.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2716-20 [12949355.001]
  • [Cites] J Nutr. 2004 Jan;134(1):48-56 [14704292.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 21;96(2):134-44 [14734703.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):423-43 [14977639.001]
  • [Cites] Nucleic Acids Res. 2000 May 15;28(10):2108-13 [10773079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):849-53 [10952104.001]
  • [Cites] Hum Mol Genet. 2001 Mar 1;10(5):433-43 [11181567.001]
  • [Cites] Trends Pharmacol Sci. 2001 Apr;22(4):195-201 [11282420.001]
  • [Cites] Mutat Res. 2001 Apr 18;475(1-2):7-20 [11295149.001]
  • [Cites] Mutat Res. 2001 Apr 18;475(1-2):57-67 [11295154.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1263-73 [11375416.001]
  • [Cites] Carcinogenesis. 2001 Jul;22(7):1019-25 [11408344.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):282-301 [11487538.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1089-96 [11588136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14853-8 [11742092.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):552-6 [11932749.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2378-84 [11956100.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5606-11 [11929966.001]
  • [Cites] Am J Clin Nutr. 2002 Aug;76(2):436-41 [12145019.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4519-24 [12154064.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2413S-2418S [12163703.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52 [12433710.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1114-21 [12615730.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):571-82 [12672676.001]
  • [Cites] Antioxid Redox Signal. 2007 Nov;9(11):1863-73 [17937580.001]
  • [Cites] Breast Cancer Res Treat. 2007 Dec;106(2):263-71 [17260091.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1097-103 [12807760.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2624-9 [14630804.001]
  • [Cites] J Nutr. 2004 Apr;134(4):750-5 [15051821.001]
  • [Cites] J Med Genet. 2004 Jun;41(6):454-8 [15173232.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1436-43 [15342443.001]
  • [Cites] J Nutr Biochem. 2004 Sep;15(9):554-60 [15350988.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Am J Clin Nutr. 1992 Jan;55(1):131-8 [1728812.001]
  • [Cites] Nat Genet. 1994 Jun;7(2):195-200 [7920641.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] Circulation. 1996 Jan 1;93(1):7-9 [8616944.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1098-102 [9067278.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Mar;17(3):569-73 [9102178.001]
  • [Cites] Atherosclerosis. 1997 Jul 11;132(1):105-13 [9247365.001]
  • [Cites] Biochem J. 1998 May 15;332 ( Pt 1):213-21 [9576870.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4158-63 [9596662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13217-20 [9789068.001]
  • [Cites] Nat Struct Biol. 1999 Apr;6(4):359-65 [10201405.001]
  • [Cites] J Nutr. 2005 Mar;135(3):389-96 [15735068.001]
  • [Cites] Mol Cell Biochem. 2005 Jan;269(1-2):37-47 [15786715.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):981-90 [15695236.001]
  • [Cites] J Nutr Biochem. 2005 Aug;16(8):467-78 [16043029.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Nutr Rev. 2005 Nov;63(11):398-407 [16370225.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2636-45 [16532039.001]
  • (PMID = 19123462.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118699; United States / NIA NIH HHS / AG / AG025834-01A2; United States / NIAAA NIH HHS / AA / R21 AA016681; United States / NIAAA NIH HHS / AA / R21 AA016681-02; United States / NIAAA NIH HHS / AA / R21 AA16681; United States / NIA NIH HHS / AG / R01 AG025834; United States / NIA NIH HHS / AG / R01 AG025834-01A2; United States / NIA NIH HHS / AG / R01 AG25834
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0LVT1QZ0BA / Homocysteine; 56HH86ZVCT / Uracil; 935E97BOY8 / Folic Acid; AE28F7PNPL / Methionine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Other-IDs] NLM/ NIHMS99332; NLM/ PMC2692263
  •  go-up   go-down


20. Basturk O, Khanani F, Sarkar F, Levi E, Cheng JD, Adsay NV: DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod Pathol; 2005 Sep;18(9):1193-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DeltaNp63 (DNp63) has become widely used, in particular, for distinguishing invasive carcinomas from noninvasive ducts by highlighting the myoepithelial or basal cells in the breast and prostate, respectively.
  • A total of 25 cases were non-neoplastic pancreata, 25 were pancreatic intraepithelial neoplasia (PanIN) of various grades, and 50 were examples of pancreatic ductal adenocarcinoma.
  • Among invasive carcinomas, it seems to be entirely specific for areas of squamous differentiation. (II) Those incidental microcysts seen in acinar lobules and lined by attenuated cells are also positive for DNp63, which suggests that they may be metaplastic in nature, and that they do not represent neoplastic cells. (III) Unlike the ducts of other exocrine organs, breast and prostate, there are no DNp63-expressing cells in the normal pancreatic ducts, and therefore, this marker cannot be used in distinguishing invasive carcinomas from the non-invasive ducts. (IV) No p63-expressing 'stem' cells are present in the pancreas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976814.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / PAR-02-068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


21. Vesely DL: Atrial natriuretic peptides: anticancer agents. J Investig Med; 2005 Nov;53(7):360-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vessel dilator, LANP, kaliuretic peptide, and ANP decrease the number of human pancreatic adenocarcinoma cells in culture by 65%, 47%, 37%, and 34%, respectively, within 24 hours at their 1 microM concentrations.
  • Similar results have been found with breast adenocarcinomas, squamous cell lung cancer, and small cell lung cancer cells, each associated with an 83% or greater inhibition of deoxyribonucleic acid (DNA) synthesis by these four peptide hormones.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line, Tumor. DNA, Neoplasm / biosynthesis. Female. Humans. Mice. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16297362.001).
  • [ISSN] 1081-5589
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 85637-73-6 / Atrial Natriuretic Factor
  • [Number-of-references] 49
  •  go-up   go-down


22. Kinkor Z, Meciarová I, Havlícek F: [Primary sebaceous carcinoma of the breast; three casuistic reports]. Ceska Gynekol; 2010 Feb;75(1):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary sebaceous carcinoma of the breast; three casuistic reports].
  • [Transliterated title] Primární sebaceózní karcinom prsu - klinicko-morfologická analogie kozní adnexální léze? Popis trí prípadů.
  • OBJECTIVE: Presentation of three cases of primary sebaceous carcinoma of the breast particularly focusing on the clinical, biological and molecular genetic aspects regarding their possible pathogenetic relationship to the Muir-Torre and Lynch syndrome.
  • Reviewed are basic principles of miscosatellite instability and dysregulations of mismatch repair genes by these inherited tumorous syndromes especially looking for morphologic and fenotypic parallels between sebaceous carcinomas of the breast and their cutaneous counterparts.
  • RESULTS: In three women aged 51 to 69 was diagnosed primary sebaceous carcinoma of the breast with maximum dimension ranged from 13 to 41 mm.


23. Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y: Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX. Cancer Res; 2006 Oct 1;66(19):9656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently reported that AF induces DNA-protein cross-links (DPC) and gamma-H2AX in MCF-7 human breast cancer cells.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Aryl Hydrocarbon Hydroxylases. Biotransformation. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Cell Line, Tumor / drug effects. Cell Line, Tumor / enzymology. Cytochrome P-450 CYP1A1 / biosynthesis. Cytochrome P-450 CYP1A1 / genetics. Cytochrome P-450 CYP1B1. Cytochrome P-450 Enzyme System / biosynthesis. Cytochrome P-450 Enzyme System / genetics. DNA Adducts. DNA, Neoplasm / drug effects. Drug Resistance, Neoplasm. Feedback, Physiological. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Microsomes, Liver / enzymology. Neoplasms / enzymology. Neoplasms / pathology. RNA, Small Interfering / pharmacology. Receptors, Aryl Hydrocarbon / physiology. Recombinant Fusion Proteins / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018623.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / DNA Adducts; 0 / DNA, Neoplasm; 0 / Flavonoids; 0 / H2AFX protein, human; 0 / Histones; 0 / Neoplasm Proteins; 0 / Prodrugs; 0 / RNA, Small Interfering; 0 / Receptors, Aryl Hydrocarbon; 0 / Recombinant Fusion Proteins; 0 / aminoflavone; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; EC 2.8.2.1 / Arylsulfotransferase; EC 2.8.2.1 / SULT1A1 protein, human
  •  go-up   go-down


24. Shi C, Hruban RH, Klein AP: Familial pancreatic cancer. Arch Pathol Lab Med; 2009 Mar;133(3):365-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, several known genetic syndromes, such as familial breast cancer (BRCA2), the Peutz-Jeghers syndrome, and the familial atypical multiple mole melanoma syndrome, have been shown to be associated with an increased risk of pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260742.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062924-140011; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / P50 CA062924-140011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 96
  •  go-up   go-down


25. Winters A, Friedlander P, Jaffe BM, Khalek MA, Moroz K, Kandil E: A postmenopausal woman with gross cystic disease fluid protein-15 and estrogen receptor-positive recurrence of papillary thyroid cancer. Thyroid; 2010 Dec;20(12):1413-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, evaluation for a possible primary breast cancer was negative.
  • This case represents an unusual presentation of a rapidly recurring papillary thyroid carcinoma masquerading immunohistochemically as a primary breast cancer.
  • [MeSH-minor] Adenocarcinoma, Papillary. Female. Humans. Thyroid Neoplasms / diagnosis. Thyroidectomy

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21054209.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Estrogen Receptor alpha; 0 / Glycoproteins; 0 / PIP protein, human; 0 / Receptors, Estrogen; 0 / estrogen receptor alpha, human
  •  go-up   go-down


26. Heinlein C, Krepulat F, Löhler J, Speidel D, Deppert W, Tolstonog GV: Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer; 2008 Apr 15;122(8):1701-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In human breast cancer, mutations in the p53 gene are associated with poor prognosis.
  • As heterogeneity of patient material and data might obscure a clear answer, we studied the effects of a coexpressed mutant p53(R270H) in transgenic mice in which SV40 early proteins initiate the development of mammary adenocarcinoma (WAP-T mice).
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Genes, p53. Mammary Neoplasms, Experimental / genetics. Mutation, Missense. Tumor Suppressor Protein p53 / genetics

  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092324.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Tumor Suppressor Protein p53; 4QD397987E / Histidine; 94ZLA3W45F / Arginine
  •  go-up   go-down


27. Yang HW, Cao J, Yang NW, Liu JL, Zhang CM, Chen JS, Hong JS, Jiang Y, Su JJ: [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance]. Ai Zheng; 2005 Jul;24(7):842-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance].
  • BACKGROUND & OBJECTIVE: The major cause of death in breast cancer patients is distant metastasis.
  • This study was to explore the expression and significance of small breast epithelial mucin (SBEM) mRNA, the specific marker of breast cancer, in peripheral blood of breast cancer patients.
  • METHODS: Expression of SBEM mRNA in peripheral blood samples from 67 breast cancer patients, 16 benign breast disease patients, and 20 healthy volunteers was detected by nested reverse transcription-polymerase chain reaction (nested RT-PCR).
  • RESULTS: SBEM mRNA was not detected in healthy volunteers and benign breast disease patients.
  • Positive rate of SBEM mRNA was 50.7% (34/67) in breast cancer patients.
  • CONCLUSION: SBEM mRNA is specifically expressed in peripheral blood of breast cancer patients, and may be a marker of micrometastasis of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Mucins / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Female. Fibroma / metabolism. Fibroma / pathology. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Estrogen / blood. Receptors, Progesterone / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004812.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUCL1 protein, human; 0 / Mucins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


28. Chalasani P, Kurtin S, Dragovich T: Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP; 2008;9(3):305-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
  • Interestingly, the patient had a strong family history of breast cancer and tested positive to germline BRCA2 mutation.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genes, BRCA2. Germ-Line Mutation. Mitomycin / administration & dosage. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469443.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 50SG953SK6 / Mitomycin
  •  go-up   go-down


29. Kumar AT, Chung E, Raymond SB, van de Water JA, Shah K, Fukumura D, Jain RK, Bacskai BJ, Boas DA: Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Opt Lett; 2009 Jul 1;34(13):2066-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We illustrate this approach using an orthotopic mouse tumor model of breast adenocarcinoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):266-76 [12001988.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14259-62 [14614130.001]
  • [Cites] Trends Cell Biol. 1999 Feb;9(2):48-52 [10087617.001]
  • [Cites] Nat Methods. 2005 Dec;2(12):905-9 [16299475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18252-7 [16344470.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044008 [19021336.001]
  • [Cites] Opt Lett. 2007 Jul 15;32(14):2034-6 [17632634.001]
  • [Cites] Mol Imaging. 2007 Jul-Aug;6(4):269-76 [17711782.001]
  • [Cites] Opt Lett. 2008 Mar 1;33(5):470-2 [18311295.001]
  • [Cites] IEEE Trans Med Imaging. 2008 Aug;27(8):1152-63 [18672432.001]
  • [Cites] Nat Protoc. 2006;1(3):1429-38 [17406431.001]
  • (PMID = 19572001.001).
  • [ISSN] 0146-9592
  • [Journal-full-title] Optics letters
  • [ISO-abbreviation] Opt Lett
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA126642; United States / NCI NIH HHS / CA / R01 CA096915-06A1; United States / NCI NIH HHS / CA / CA85140; United States / NIA NIH HHS / AG / R01 AG026240-01A1; United States / NCI NIH HHS / CA / CA080124-06A2; United States / NCI NIH HHS / CA / P01 CA080124-06A2; United States / NCI NIH HHS / CA / P01 CA080124-09; United States / NCI NIH HHS / CA / R01 CA085140-10; United States / NCI NIH HHS / CA / R01 CA115767-04; United States / NCI NIH HHS / CA / R01 CA085140; United States / NCI NIH HHS / CA / CA126642; United States / NCI NIH HHS / CA / CA80124; United States / NCI NIH HHS / CA / CA096915-06A1; United States / NCI NIH HHS / CA / R01 CA126642-02; United States / NCI NIH HHS / CA / CA085140-10; United States / NCI NIH HHS / CA / R01 CA115767-01A1; United States / NCI NIH HHS / CA / P01 CA080124; United States / NCI NIH HHS / CA / R24 CA085140; United States / NCI NIH HHS / CA / CA96915; United States / NCI NIH HHS / CA / R01 CA085140-09; United States / NCI NIH HHS / CA / CA080124-09; United States / NIA NIH HHS / AG / R01 AG026240; United States / NCI NIH HHS / CA / P01 CA080124-01A1; United States / NCI NIH HHS / CA / R01 CA115767; United States / NCI NIH HHS / CA / R01 CA096915; United States / NIA NIH HHS / AG / AG026240; United States / NCI NIH HHS / CA / CA115767
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Luminescent Proteins
  • [Other-IDs] NLM/ NIHMS192347; NLM/ PMC2872111
  •  go-up   go-down


30. Zhou XF, Zhang L, Tseng E, Scott-Ramsay E, Schentag JJ, Coburn RA, Morris ME: New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug Metab Dispos; 2005 Mar;33(3):321-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efflux of cytotoxic agents mediated by P-glycoprotein is believed to be an important mechanism of multidrug resistance, which remains a serious limitation to successful chemotherapy in cancers such as metastatic breast cancer.
  • [(3)H]Vinblastine accumulation studies indicated that at a concentration level of 3 muM, 15 of 18 4-aryl-1,4-dihydropyridines and all 4-arylpyridines can successfully restore intracellular accumulation of vinblastine in a resistant human breast adenocarcinoma cell line, MCF-7/adr, which overexpresses P-glycoprotein.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585608.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Calcium Channels; 0 / Dihydropyridines; 0 / P-Glycoprotein; 0 / Pyridines; 5V9KLZ54CY / Vinblastine; Z81N45O25Z / niguldipine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


31. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN: Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol; 2005 Oct;16(10):1365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the effects of liposomal chemotherapeutic agent, nanoparticle size, and liposome circulation time on tissue coagulation and intratumoral drug uptake when radiofrequency (RF) ablation is combined with adjuvant intravenous liposomal chemotherapy in an animal breast tumor model.
  • MATERIALS AND METHODS: Ninety-one R3230 mammary adenocarcinoma nodules were implanted in 48 Fischer rats.
  • [MeSH-major] Adenocarcinoma / therapy. Antibiotics, Antineoplastic / therapeutic use. Catheter Ablation. Doxorubicin / therapeutic use. Mammary Neoplasms, Experimental / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221908.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA87992-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Maki RG: Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol; 2010 Nov 20;28(33):4985-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent developments regarding phase I to II clinical trials of such agents are discussed, as well as potential studies to consider in the future, given the lack of efficacy of one such monoclonal antibody in combination with cytotoxic chemotherapy in a first-line study in metastatic non-small-cell lung adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2010 Feb;162(2):249-57 [19917654.001]
  • [Cites] Sci Signal. 2010;3(108):ra10 [20145208.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):327-35 [19337828.001]
  • [Cites] Cell. 2010 Apr 2;141(1):69-80 [20371346.001]
  • [Cites] Mol Cancer Ther. 2010 May;9(5):1286-97 [20457621.001]
  • [Cites] J Pathol. 2010 Jul;221(3):300-7 [20527023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11122-7 [20534466.001]
  • [Cites] Cancer Res. 2010 Aug 15;70(16):6412-9 [20710042.001]
  • [Cites] Clin Cancer Res. 2010 Sep 15;16(18):4654-65 [20670944.001]
  • [Cites] Cell Res. 2001 Jun;11(2):107-15 [11453542.001]
  • [Cites] Growth Horm IGF Res. 2001 Oct;11(5):289-97 [11735247.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2941-7 [11753970.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7 [11752009.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):454-60 [11904318.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] J Endocrinol. 2002 Oct;175(1):33-40 [12379488.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6035-8 [12414625.001]
  • [Cites] Nature. 2003 Jan 9;421(6919):182-7 [12483226.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3299-304 [12843179.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):803-8 [14506643.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2211-22 [14657428.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):83-8 [14715249.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):958-60 [15314640.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 27;321(3):524-30 [15358139.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6134-42 [15448000.001]
  • [Cites] Nature. 1976 Dec 9;264(5586):542-5 [1004590.001]
  • [Cites] J Biol Chem. 1978 Apr 25;253(8):2769-76 [632300.001]
  • [Cites] Acta Paediatr Scand Suppl. 1977;(270):15-25 [356516.001]
  • [Cites] FEBS Lett. 1983 Sep 5;161(1):117-21 [6350044.001]
  • [Cites] Am J Gastroenterol. 1985 Apr;80(4):266-9 [3984995.001]
  • [Cites] Annu Rev Physiol. 1985;47:443-67 [2986538.001]
  • [Cites] FEBS Lett. 1985 Sep 9;189(1):115-8 [3896851.001]
  • [Cites] N Engl J Med. 1988 Dec 1;319(22):1434-40 [3185662.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Jan;32(1):65-71 [2331812.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Nov;33(5):593-603 [1701371.001]
  • [Cites] J Clin Invest. 1990 Dec;86(6):1806-14 [2174908.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Aug 30;179(1):579-85 [1715698.001]
  • [Cites] Cancer. 1991 Oct 15;68(8):1673-7 [1913507.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19665-72 [15757893.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1829-33 [16123266.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11118-28 [16322262.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Genes Dev. 2006 Feb 1;20(3):267-75 [16452501.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12743-50 [16517595.001]
  • [Cites] Mutat Res. 2006 Mar 20;595(1-2):117-24 [16448675.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):788-96 [16575403.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40 [16740780.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):597-604 [16827799.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):395-407 [16932322.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1898-908 [16986125.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):69-74 [16458427.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D237-40 [17135202.001]
  • [Cites] Mol Cancer Ther. 2007 Feb;6(2):667-74 [17308062.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1438-44 [17332286.001]
  • [Cites] Growth Horm IGF Res. 2007 Feb;17(1):54-7 [17166755.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):700-6 [17320820.001]
  • [Cites] J Pathol. 2007 Apr;211(5):550-4 [17299733.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3431-40 [17409454.001]
  • [Cites] Science. 2007 Apr 6;316(5821):112-5 [17412960.001]
  • [Cites] Nat Med. 2007 Jun;13(6):748-53 [17496901.001]
  • [Cites] Arch Biochem Biophys. 2007 Sep 15;465(2):359-69 [17644060.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] Adv Exp Med Biol. 2007;612:104-18 [18161484.001]
  • [Cites] J Intern Med. 2008 Feb;263(2):179-91 [18226095.001]
  • [Cites] Endocrinology. 2008 Mar;149(3):1214-26 [18039785.001]
  • [Cites] FASEB J. 2008 Mar;22(3):807-18 [17928362.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1538-45 [18316619.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2007;72:483-8 [18419308.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3204-15 [18483389.001]
  • [Cites] Front Biosci. 2008;13:3906-12 [18508484.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92 [18550829.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1293-8 [18372285.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Nature. 1992 Oct 8;359(6395):554-6 [1406976.001]
  • [Cites] Cell. 1993 Oct 8;75(1):59-72 [8402901.001]
  • [Cites] J Intern Med. 1993 Dec;234(6):543-52 [7505031.001]
  • [Cites] J Endocrinol. 1993 Sep;138(3):545-54 [7506292.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2803-7 [8168113.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4588-95 [8007963.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3286-95 [8045259.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1635-41 [7895674.001]
  • [Cites] J Biol Chem. 1995 Jun 9;270(23):13589-92 [7539790.001]
  • [Cites] Nat Genet. 1995 Jun;10(2):196-201 [7663515.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1545-50 [8603400.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19304-9 [8702614.001]
  • [Cites] Pediatr Res. 1996 Jun;39(6):992-8 [8725260.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):634-41 [8814167.001]
  • [Cites] J Clin Invest. 1996 Dec 1;98(11):2612-5 [8958225.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-3-S10-10 [9275000.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Blood Press. 1998 May;7(2):89-95 [9657535.001]
  • [Cites] Int Rev Cytol. 1998;183:1-94 [9666565.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2383-90 [9796969.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 [10203281.001]
  • [Cites] J Lab Clin Med. 1957 Jun;49(6):825-36 [13429201.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jan 14;229(1-2):149-60 [15607539.001]
  • [Cites] Endocrinology. 2005 Feb;146(2):851-60 [15498882.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1563-71 [15746061.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3868-76 [15867386.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3196-203 [18474873.001]
  • [Cites] PLoS One. 2008;3(7):e2578 [18596909.001]
  • [Cites] Nature. 2008 Jul 17;454(7202):345-9 [18528331.001]
  • [Cites] Cell. 2008 Aug 8;134(3):405-15 [18674809.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2589-98 [18765823.001]
  • [Cites] J Endocrinol. 2008 Oct;199(1):69-80 [18653623.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8039-48 [18829562.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):3098-103 [18802403.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1860-9 [18641009.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):639-57 [18971124.001]
  • [Cites] J Pathol. 2008 Dec;216(4):428-39 [18855347.001]
  • [Cites] Cancer Cell. 2008 Dec 9;14(6):447-57 [19061836.001]
  • [Cites] J Pathol. 2009 Mar;217(4):469-82 [19148905.001]
  • [Cites] FEBS J. 2009 Mar;276(5):1221-32 [19175674.001]
  • [Cites] Pediatr Dev Pathol. 2009 Mar-Apr;12(2):127-35 [18788888.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):725-31 [19279572.001]
  • [Cites] Nature. 2009 Apr 23;458(7241):1056-60 [19262508.001]
  • [Cites] Anticancer Res. 2009 Apr;29(4):1131-5 [19414355.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):307-13 [19508836.001]
  • [Cites] Nat Rev Endocrinol. 2009 Jul;5(7):367-73 [19455179.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):914-21 [19407853.001]
  • [Cites] Nature. 2009 Jul 16;460(7253):392-5 [19587680.001]
  • [Cites] Semin Oncol. 2009 Aug;36(4):338-46 [19664494.001]
  • [Cites] Science. 2009 Oct 2;326(5949):140-4 [19797661.001]
  • [Cites] Lancet. 2009 Oct 3;374(9696):1196-208 [19801098.001]
  • [Cites] PLoS One. 2009;4(10):e7273 [19806209.001]
  • [Cites] Endocr Regul. 2009 Oct;43(4):149-55 [19908933.001]
  • [Cites] Eur J Hum Genet. 2009 Dec;17(12):1668-75 [19491931.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5800-7 [19786654.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1128-33 [10534157.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):1-9 [10699960.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1598-600 [10770203.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1101-7 [11007947.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33607-13 [10874028.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • (PMID = 20975071.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA148260; United States / NCI NIH HHS / CA / RC2 CA148260; United States / NCI NIH HHS / CM / CM62202; United States / NCI NIH HHS / CA / CA47179; United States / NCI NIH HHS / CA / N01CM62202; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Somatomedins; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Other-IDs] NLM/ PMC3039924
  •  go-up   go-down


33. Mul VE, Verschueren TA, van Geest AJ, Baumert BG: Bullous pemphigoid (BP) induced by radiotherapy. Radiother Oncol; 2007 Jan;82(1):105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Breast Neoplasms / radiotherapy. Pemphigoid, Bullous / etiology

  • Genetic Alliance. consumer health - Bullous Pemphigoid.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Radiother Oncol. 2007 Jan;82(1):5-9 [17161479.001]
  • (PMID = 17161480.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Ireland
  •  go-up   go-down


34. Impidjati, Leonard F, Thielecke H: Evaluation of a capillary measuring system for the characterisation of small tissue samples by impedance spectroscopy at higher frequencies. Conf Proc IEEE Eng Med Biol Soc; 2005;1:678-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, the applicability of a capillary measuring system to record the impedance of a biological sample over a wide frequency range is evaluated using a suspension of human breast adenocarcinoma cells (MCF-7).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17282273.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Alshoukr F, Rosant C, Maes V, Abdelhak J, Raguin O, Burg S, Sarda L, Barbet J, Tourwé D, Pelaprat D, Gruaz-Guyon A: Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors. Bioconjug Chem; 2009 Aug 19;20(8):1602-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The increased expression of the neurotensin (NT) receptor NTS1 by different cancer cells, such as pancreatic adenocarcinoma and ductal breast cancer cells, as compared to normal epithelium, offers the opportunity to target these tumors with radiolabeled neurotensin analogues for diagnostic or therapeutic purposes.
  • The DTPA-NT-20.3 peptide is a promising candidate for imaging neurotensin receptor-positive tumors, such as pancreatic adenocarcinoma and invasive ductal breast cancer.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Animals. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Cell Line, Tumor. Female. Humans. Ligands. Mice. Mice, Inbred BALB C. Mice, Nude. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism. Tissue Distribution

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19610615.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Ligands; 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor; 39379-15-2 / Neurotensin; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


36. Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H: Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer; 2008;8:70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. HSP70 Heat-Shock Proteins / metabolism. Heat-Shock Proteins / metabolism. Membrane Proteins / metabolism. Molecular Chaperones / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Oncol Rep. 2003 May;5(3):203-9 [12667417.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1300-10 [15339968.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1994;4(1):1-18 [7987045.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Breast Cancer Res Treat. 1999 Mar;54(2):135-46 [10424404.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):429-32 [15637761.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):1056-9 [15742415.001]
  • [Cites] World J Gastroenterol. 2005 Apr 14;11(14):2072-9 [15810071.001]
  • [Cites] Cell Stress Chaperones. 2005 Spring;10(1):46-58 [15832947.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):55-62 [15949590.001]
  • [Cites] Cell Stress Chaperones. 2005 Summer;10(2):86-103 [16038406.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Trends Biochem Sci. 2001 Aug;26(8):504-10 [11504627.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):35-41 [11525305.001]
  • [Cites] Scand J Gastroenterol Suppl. 2001;(234):51-60 [11768562.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):123-30 [11756233.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] FEBS Lett. 2007 Jul 31;581(19):3641-51 [17481612.001]
  • [Cites] Cancer Detect Prev. 2005;29(6):544-51 [16297569.001]
  • [Cites] N Engl J Med. 2005 Dec 29;353(26):2821-2; author reply 2821-2 [16382552.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):308-15 [16182273.001]
  • [Cites] Curr Mol Med. 2006 Feb;6(1):45-54 [16472112.001]
  • [Cites] Arch Biochem Biophys. 2006 Mar 15;447(2):155-66 [16497268.001]
  • [Cites] Electrophoresis. 2006 May;27(9):1840-52 [16645950.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7849-53 [16912156.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):741-4 [16861902.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5987-93 [17062670.001]
  • [Cites] Toxicology. 2007 Jan 18;229(3):253-61 [17161515.001]
  • [Cites] Cell Stress Chaperones. 2006 Winter;11(4):334-42 [17278882.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3496-9 [17440054.001]
  • [Cites] Recent Results Cancer Res. 2000;155:1-14 [10693234.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Mar 15;163(3):260-6 [10702365.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jan;59(1):15-26 [10752676.001]
  • [Cites] J Cell Biochem. 2000 Apr;77(3):396-408 [10760948.001]
  • [Cites] Cell Stress Chaperones. 2004 Mar;9(1):76-87 [15270080.001]
  • (PMID = 18331622.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Proteins; 0 / Molecular Chaperones; 0 / RNA, Messenger; 0 / glucose-regulated proteins; 0 / molecular chaperone GRP78
  • [Other-IDs] NLM/ PMC2270853
  •  go-up   go-down


37. Murphy JP, Pinto DM: Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. Proteomics; 2010 May;10(9):1847-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells.
  • We explored proteomic changes resulting from insulin-like growth factor 1 stimulation of MCF-7 adenocarcinoma cells as a function of time.
  • [MeSH-major] Adenocarcinoma / chemistry. Breast Neoplasms / chemistry. Receptor, IGF Type 1 / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213678.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


38. Orell SR, Miliauskas J: Fine needle biopsy cytology of breast lesions: a review of interpretative difficulties. Adv Anat Pathol; 2005 Sep;12(5):233-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle biopsy cytology of breast lesions: a review of interpretative difficulties.
  • Screening mammography and greater community awareness of breast carcinoma have led to an increase in fine needle biopsies of the breast.
  • As a consequence, a wide variety of cytologic patterns have been encountered and studied in benign, proliferative, and malignant breast lesions.
  • We review the main reasons for diagnostic difficulties in breast cytology, the situations in which either a false positive or a false negative diagnosis is possible, as well as conditions whose incorrect typing can lead to inappropriate management.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210919.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


39. Kojić V, Bogdanović G, Jakimov D, Duran IM: Synthesis and antiproliferative activity of new carboplatin analogues. J BUON; 2005 Oct-Dec;10(4):541-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The compounds were tested for antiproliferative activity against the following human tumor cell lines: myelogenous leukemia K562, colon adenocarcinoma HT- 29, breast adenocarcinoma MCF-7, and human lung fetal fibroplast cell line MRC-5.
  • Colon adenocarcinoma cell line HT-29 was found to be 4-fold less sensitive to MD2 but equally sensitive to MD3 with respect to carboplatin referent compound.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357214.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


40. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer; 2010;9:121
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Drug Resistance, Neoplasm / genetics. Proto-Oncogene Proteins c-met / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Receptors, Growth Factor / metabolism. Signal Transduction / physiology. Stomach Neoplasms / metabolism


41. Kruse AL, Luebbers HT, Obwegeser JA, Edelmann L, Graetz KW: Temporomandibular disorders associated with metastases to the temporomandibular joint: a review of the literature and 3 additional cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Aug;110(2):e21-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor was most commonly found in the breast (34%), followed by the lung (21%).
  • Adenocarcinoma was predominant (72.97%).
  • CONCLUSION: Establishing an exact diagnosis of metastatic lesions in the TMJ can provide a diagnostic challenge.
  • Clinicians should include the suspicion of cancer in the differential diagnosis, in particular when patients have a previous history of malignant neoplasm or do not respond to treatment appropriately.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma / secondary. Mandibular Condyle / pathology. Mandibular Neoplasms / secondary. Temporomandibular Joint Disorders / etiology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / pathology. Female. Humans. Lung Neoplasms / pathology. Male

  • MedlinePlus Health Information. consumer health - Temporomandibular Joint Dysfunction.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20659692.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


42. Vesely DL: Cardiac and renal hormones: anticancer effects in vitro and in vivo. J Investig Med; 2009 Jan;57(1):22-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Four cardiovascular hormones, ie, vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide each at 1 mmol/L, decrease up to 97% of human breast, ovarian, pancreatic, colon, kidney, and prostate adenocarcinoma cells, as well as small cell and squamous cell lung cancer cells within 24 hours.
  • Similarly, two thirds of human breast cancers in athymic mice can be eliminated without surgery with these cardiac hormones.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092678.001).
  • [ISSN] 1081-5589
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Natriuretic Peptides
  • [Number-of-references] 76
  •  go-up   go-down


43. Nagaoka R, Iwasaki T, Rokutanda N, Takeshita A, Koibuchi Y, Horiguchi J, Shimokawa N, Iino Y, Morishita Y, Koibuchi N: Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine; 2006 Dec;30(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells.
  • Although CYP3A4, MDR1, and SXR are expressed mainly in the liver and the small intestine, these gene products are also expressed in breast cancer cells.
  • Because tamoxifen (TAM) is known to be metabolized by CYP3A4 and P-glycoprotein, we investigated the effect of TAM on these SXR-targeted genes in breast cancer cells.
  • These results suggest that TAM induces CYP3A4 and MDR1 gene expression through SXR, which may affect TAM metabolic pathway in breast cancer cells.
  • [MeSH-minor] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Cell Line, Tumor. Cytochrome P-450 CYP3A. Dose-Response Relationship, Drug. Estrogen Antagonists / metabolism. Gene Expression Regulation, Neoplastic. Genes, MDR. Humans. RNA, Messenger / metabolism. Retinoid X Receptors / metabolism. Transcription, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2001 Oct;145(4):513-7 [11581012.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3446-50 [8758910.001]
  • [Cites] Biopharm Drug Dispos. 1981 Oct-Dec;2(4):381-90 [7317574.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4190-3 [10485452.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 27;267(3):756-60 [10673364.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7316-39 [14576841.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6212-7 [10823961.001]
  • [Cites] Gastroenterology. 1992 Mar;102(3):879-85 [1347031.001]
  • [Cites] Br J Clin Pharmacol. 1995 Dec;40(6):523-30 [8703657.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32453-8 [12072427.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12208-13 [9770465.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2103-7 [10473093.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1522-33 [14973112.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):57-63 [8318421.001]
  • [Cites] N Engl J Med. 1998 Nov 26;339(22):1609-18 [9828250.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27645-53 [9765300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8 [2444983.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Biochem Pharmacol. 1991 Jun 15;41(12):1911-9 [2039544.001]
  • [Cites] J Clin Invest. 1998 Sep 1;102(5):1016-23 [9727070.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;949:345-8 [11795374.001]
  • [Cites] Nat Med. 2001 May;7(5):584-90 [11329060.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3402-6 [9270005.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1422-8 [2466554.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 7;84(19):1506-12 [1359153.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:389-430 [9597161.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75 [15159443.001]
  • [Cites] Endocr Rev. 2002 Oct;23(5):687-702 [12372848.001]
  • [Cites] Science. 2001 Jun 22;292(5525):2329-33 [11408620.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2465-8 [11923541.001]
  • [Cites] Clin Pharm. 1988 Jun;7(6):454-7 [3402181.001]
  • [Cites] Pharmacol Rev. 2001 Mar;53(1):25-71 [11171938.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):14581-7 [11297522.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27629-34 [9346901.001]
  • [Cites] Drug Metab Dispos. 1996 Aug;24(8):899-905 [8869826.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34283-93 [10567404.001]
  • [Cites] J Pharm Pharmacol. 2004 Aug;56(8):985-91 [15285842.001]
  • [Cites] Br J Cancer. 1987 May;55(5):509-12 [3606944.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3195-205 [9784494.001]
  • (PMID = 17526937.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / Receptors, Steroid; 0 / Retinoid X Receptors; 0 / pregnane X receptor; 094ZI81Y45 / Tamoxifen; 17197F0KYM / afimoxifene; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


44. Thorne LB, Ryan JL, Elmore SH, Glaser SL, Gulley ML: Real-time PCR measures Epstein-Barr Virus DNA in archival breast adenocarcinomas. Diagn Mol Pathol; 2005 Mar;14(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time PCR measures Epstein-Barr Virus DNA in archival breast adenocarcinomas.
  • The role of Epstein-Barr Virus (EBV) in breast cancer pathogenesis remains controversial.
  • Fifty-five cases of paraffin-embedded, formalin-fixed invasive breast cancer were screened for the presence of EBV using quantitative polymerase chain reaction (PCR) directed at five different targets within the EBV genome (BamH1W, LMP1, EBNA1, LMP2, and BZLF1 regions).
  • In conclusion, EBV DNA is detectable in a fraction of breast cancer specimens using real-time PCR as a screening tool, albeit at quite low levels, which suggests that only rare cells are infected.
  • [MeSH-major] Adenocarcinoma / virology. Breast Neoplasms / virology. DNA, Viral / genetics. DNA, Viral / isolation & purification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714061.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


45. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol; 2010 Dec;33(6):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 positive breast cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Quinazolines / therapeutic use


46. Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, Corley DA, Sharp L, Lagergren J, Barrett's Esophagus, Adenocarcinoma Consortium (BEACON) Investigators: Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer; 2010 Jul;46(11):2067-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis.
  • BACKGROUND: The rapidly rising incidence and the striking male predominance are as yet unexplained features of oesophageal and gastric junction adenocarcinoma.
  • We therefore pooled data on women from four population-based case-control studies to examine the association of female reproductive and sex hormonal factors with oesophageal and gastric junction adenocarcinoma.
  • Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for a range of reproductive factors, adjusted for age, study and major risk factors for oesophageal and gastric junction adenocarcinoma.
  • Among parous women, a reduced risk of oesophageal and gastric junction adenocarcinoma was found after breastfeeding (OR=0.58, 95% CI=0.37-0.92) and the risk decreased with increased duration of breastfeeding (>12 months OR=0.42, 95% CI=0.23-0.77).
  • The endogenous reproductive factors such as parity, menstruation, history of pregnancy and the exogenous factors such as use of oral contraceptives and of hormone replacement therapy were not statistically significantly associated with oesophageal and gastric junction adenocarcinoma.
  • CONCLUSION: Our findings suggest that breastfeeding is associated with a decreased risk of oesophageal and gastric junction adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Breast Feeding. Esophageal Neoplasms / epidemiology. Esophagogastric Junction. Gonadal Steroid Hormones / physiology

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2919-24 [15517897.001]
  • [Cites] Curr Treat Options Oncol. 2009 Apr;10(1-2):67-81 [19603272.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):3107-14 [11712819.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] Am J Med. 2003 Aug 18;115 Suppl 3A:179S-187S [12928099.001]
  • [Cites] Epidemiol Rev. 1993;15(1):36-47 [8405211.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):636-42 [12594820.001]
  • [Cites] Regul Pept. 2004 Jun 15;119(1-2):39-44 [15093695.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Int J Epidemiol. 2009 Feb;38(1):312-8 [18775873.001]
  • [Cites] Obstet Gynecol. 1985 Jun;65(6):785-8 [3923412.001]
  • [Cites] Med J Aust. 2008 Sep 1;189(5):254-6 [18759719.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):189-93 [18000501.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1459-61 [12168823.001]
  • [Cites] Nutr Res Rev. 1997 Jan;10(1):35-56 [19094257.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6379-91 [15322512.001]
  • [Cites] Endocrine. 2000 Aug;13(1):1-10 [11051041.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Eur J Cancer Prev. 2007 Apr;16(2):124-9 [17297388.001]
  • [Cites] Br J Cancer. 2008 Nov 4;99(9):1506-10 [18841152.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Infect Dis Obstet Gynecol. 1999;7(4):195-8 [10449268.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1413-7, 1417.e1-2 [17997357.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):859-61 [16189516.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] Dis Esophagus. 2003;16(1):17-23 [12581249.001]
  • [Cites] Gut. 2004 Aug;53(8):1064-5 [15247167.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):88-93 [2731125.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):3-6 [8289449.001]
  • [Cites] Phys Rev Lett. 2009 Mar 6;102(9):092002 [19392513.001]
  • [Cites] Cancer Lett. 2003 Nov 25;201(2):225-36 [14607338.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2694-9 [18853967.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):341-54 [11476557.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):303-8 [16839227.001]
  • [Cites] Scand J Gastroenterol. 2008 Mar;43(3):323-7 [18938769.001]
  • [Cites] Int J Cancer. 2003 Oct 10;106(6):982-3 [12918081.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):87-101 [20094044.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):66-72 [12837713.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] Br J Surg. 2001 Sep;88(9):1249-57 [11531876.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1117-23 [15561642.001]
  • [Cites] Histopathology. 2003 Jan;42(1):95-6 [12493034.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • (PMID = 20456945.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK063616; United States / NIDDK NIH HHS / DK / R01 DK63616; United Kingdom / Chief Scientist Office / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  •  go-up   go-down


47. Kaprara A, Pazaitou-Panayiotou K, Chemonidou MC, Constantinidis TC, Lambropoulou M, Koffa M, Kiziridou A, Kakolyris S, Kortsaris A, Chatzaki E: Distinct distribution of corticotropin releasing factor receptors in human breast cancer. Neuropeptides; 2010 Oct;44(5):355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct distribution of corticotropin releasing factor receptors in human breast cancer.
  • In experimental models of breast cancer CRF has been shown to exert anti-proliferative and other actions.
  • Aim of the present study was to describe the expression of the two types of CRF receptors CRF(1) and CRF(2) in human breast tumors.
  • Receptor expression was studied in breast biopsies from patients diagnosed for primary breast adenocarcinoma, obtained from the tumor and the adjacent benign tissue.
  • Histological mapping using immunohistochemistry revealed positive CRF(1) immunostaining in the cancerous implants and breast ducts, whereas CRF(2) immunoreactivity was localized mainly in the perineural invasions.
  • In conclusion, both CRF receptors were found in breast cancer and the respective benign adjacent tissue.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Receptors, Corticotropin-Releasing Hormone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20630588.001).
  • [ISSN] 1532-2785
  • [Journal-full-title] Neuropeptides
  • [ISO-abbreviation] Neuropeptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Corticotropin-Releasing Hormone
  •  go-up   go-down


48. VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL: High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol; 2009 Jul;175(1):355-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model.
  • Non-alcoholic fatty liver disease (NAFLD), which includes steatosis and its progression to non-alcoholic steatohepatitis, is a liver disorder of increasing clinical significance.
  • Here we characterize a murine model of high fat diet-induced NAFLD with progression from liver steatosis to histological features compatible with steatohepatitis and more advanced stages of NAFLD in humans, including chronic portal inflammation, pericellular and bridging fibrosis, Mallory body formation, and bile ductular reaction.
  • Chronic changes induced by the prolonged consumption of a high-fat diet alone culminate in the development of primary liver dysplasias.
  • Importantly, we extend these studies to demonstrate that even the early stages of uncomplicated steatosis provide a permissive microenvironment for the growth of colon cancer cells that are metastatic to the liver.
  • High fat diet-induced steatosis, coupled with a splenic injection model of experimental liver metastasis using syngeneic MC38 colon cancer cells, resulted in an increased number of secondary tumor nodules and metastatic burden in steatotic livers.
  • Metastatic nodules were associated with focal peritumoral areas of infiltrating inflammatory cells and associated apoptotic cell populations.
  • These results suggest that the modulation of specific host factors in the steatotic liver contributes to tumor progression in the microenvironment of NAFLD.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2007 Sep;42(9):1023-30 [17710666.001]
  • [Cites] Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63 [17605315.001]
  • [Cites] Curr Opin Lipidol. 2008 Feb;19(1):25-9 [18196983.001]
  • [Cites] Clin Sci (Lond). 2008 Apr;114(7):457-66 [18302533.001]
  • [Cites] Curr Drug Targets. 2008 May;9(5):375-80 [18473765.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(2):329-42 [17939036.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):204-15 [18448242.001]
  • [Cites] Cytokine. 2008 Sep;43(3):374-9 [18701317.001]
  • [Cites] Arch Pathol Lab Med. 2008 Nov;132(11):1761-6 [18976012.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Digestion. 2009;79 Suppl 1:26-32 [19153487.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Semin Liver Dis. 2001;21(1):89-104 [11296700.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5016-23 [11431335.001]
  • [Cites] Eur J Immunol. 2001 Jul;31(7):1981-8 [11449350.001]
  • [Cites] Jpn J Cancer Res. 2002 Feb;93(2):125-32 [11856475.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):679-90 [12406439.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):1-10 [12925950.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):114-8 [15221653.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):60-6 [15246209.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S97-103 [15508109.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2083-128 [7388781.001]
  • [Cites] Lab Invest. 1988 Dec;59(6):848-56 [2462130.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):505-13 [2466401.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):809-14 [9148753.001]
  • [Cites] Liver Int. 2005 Apr;25(2):294-304 [15780053.001]
  • [Cites] J Leukoc Biol. 2005 Apr;77(4):552-9 [15629884.001]
  • [Cites] Obes Surg. 2005 Mar;15(3):442-6 [15826485.001]
  • [Cites] Diabetologia. 2005 Apr;48(4):634-42 [15747110.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):173-7 [15908310.001]
  • [Cites] Diabet Med. 2005 Sep;22(9):1129-33 [16108837.001]
  • [Cites] Front Biosci. 2006;11:479-91 [16146745.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):291-3 [16231592.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1079-86 [17164441.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):495-500 [17417772.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):17-23, vii [17544969.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):830-9 [17211838.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):556-64 [17459514.001]
  • (PMID = 19541928.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50CA095103; United States / NCI NIH HHS / CA / P50 CA095103; United States / NIDDK NIH HHS / DK / P30 DK058404; United States / NCI NIH HHS / CA / R01CA060867; United States / NIDDK NIH HHS / DK / K08 DK70708-01; United States / NIDDK NIH HHS / DK / P30DK058404; United States / NIDDK NIH HHS / DK / K08 DK070708; United States / NCI NIH HHS / CA / R01 CA060867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ PMC2708821
  •  go-up   go-down


49. Gao S, Liu Q, Wang X, Lin B, Zhang S: Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. Med Oncol; 2010 Sep;27(3):960-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Lewis Blood-Group System / physiology. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11961-72 [15655247.001]
  • [Cites] Adv Exp Med Biol. 2001;491:369-402 [14533809.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1321-6 [16995873.001]
  • [Cites] Biochemistry. 2008 Jul 8;47(27):7097-107 [18553932.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R780-7 [16168124.001]
  • [Cites] Hum Cell. 1988 Dec;1(4):426-35 [3154025.001]
  • [Cites] Gene Expr. 1995;4(3):95-109 [7734951.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5269-77 [11016657.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Jun;30(3):284-9 [18686606.001]
  • [Cites] Mol Cancer. 2007 May 09;6:32 [17488527.001]
  • [Cites] Cancer Sci. 2009 Mar;100(3):546-51 [19154404.001]
  • [Cites] J Biochem. 2007 Mar;141(3):309-17 [17190787.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):26-30 [15649251.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2282-92 [10829049.001]
  • [Cites] Cell Cycle. 2006 Dec;5(23):2820-6 [17172846.001]
  • [Cites] Mol Biol Cell. 2009 Jun;20(12 ):2856-63 [19369415.001]
  • [Cites] Eur J Gynaecol Oncol. 2009;30(3):303-8 [19697627.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):854-62 [15609299.001]
  • [Cites] Ai Zheng. 2008 Sep;27(9):934-41 [18799031.001]
  • [Cites] Cancer Lett. 2007 Jul 18;252(2):225-34 [17276588.001]
  • [Cites] Cytogenet Genome Res. 2009;125(1):8-18 [19617691.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):415-22 [19211583.001]
  • (PMID = 19771531.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Lewis Blood-Group System; 0 / Lewis Y antigen; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Recombinant Fusion Proteins; 4AF605U6JN / multidrug resistance-associated protein 2; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.69 / galactoside 2-alpha-L-fucosyltransferase; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C-alpha; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.2 / TOP1 protein, human; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down


50. Airoldi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G, Truini M, Grossi F, Galietta LJ, Ribatti D, Pistoia V: IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One; 2009;4(7):e6119
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.
  • Aim of the study was to investigate i) IL-12Rbeta2 expression in human primary lung adenocarcinomas and in their counterparts, i.e. normal bronchial epithelial cells (NBEC), ii) the direct anti-tumor activity of IL-12 on lung adenocarcinoma cells in vitro and vivo, and the mechanisms involved, and iii) IL-12 activity on NBEC.
  • IL-12 treatment of IL-12R(+) neoplastic cells isolated from primary adenocarcinoma (n = 6) inhibited angiogenesis in vitro through down-regulation of different pro-angiogenic genes (e.g.
  • CONCLUSIONS: This study demonstrates that IL-12 inhibits directly the growth of human lung adenocarcinoma and targets the adjacent NBEC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bronchi / pathology. Interleukin-12 / pharmacology. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2006 Mar;18(2):151-5 [16462184.001]
  • [Cites] Clin Immunol. 2006 Feb-Mar;118(2-3):159-69 [16271513.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):717-27 [16520032.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3978-80 [16618714.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):75-9 [16755294.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4300-9 [16518408.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1357-62 [17237382.001]
  • [Cites] Lung Cancer. 2007 Apr;56(1):25-33 [17175059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3996-4001 [17360466.001]
  • [Cites] Nat Protoc. 2006;1(1):85-91 [17406216.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4940-8 [17510424.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69 [17686824.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2636-42 [17602269.001]
  • [Cites] Lung Cancer. 2007 Nov;58(2):205-13 [17686546.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3660-3 [18060028.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1261-72 [18027871.001]
  • [Cites] Blood. 2008 Aug 1;112(3):750-9 [18474725.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2669-76 [19276384.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3846-56 [18060032.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):623-31 [10653877.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1111-6 [10706132.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1678-92 [10815886.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Jun;278(6):L1186-94 [10835324.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):839-45 [11777980.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):264-9 [11875427.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68 [11900991.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):729-37 [12576442.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1054-8 [15057248.001]
  • [Cites] J Clin Invest. 2004 Jun;113(11):1651-9 [15173892.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] J Exp Med. 1993 Oct 1;178(4):1223-30 [8104230.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14002-7 [8943050.001]
  • [Cites] J Vasc Res. 1997 Nov-Dec;34(6):455-63 [9425998.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jun;34(6):478-81 [9661051.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):361-5 [9766572.001]
  • [Cites] Am J Physiol. 1998 Nov;275(5 Pt 1):L917-23 [9815109.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1970-6 [15545974.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):209-12 [15692764.001]
  • [Cites] Annu Rev Immunol. 2005;23:1-21 [15771564.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3846-53 [16081683.001]
  • (PMID = 19582164.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2702099
  •  go-up   go-down


51. Simpson RH, Desai S, Di Palma S: Salivary duct carcinoma in situ of the parotid gland. Histopathology; 2008 Oct;53(4):416-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Salivary duct carcinoma in situ is morphologically similar to breast ductal carcinoma in situ and, although our cases are few, salivary duct carcinoma in situ can possibly be subdivided into luminal and non-luminal cell types, as can analogous mammary neoplasms.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Receptor, ErbB-2 / metabolism. Receptors, Androgen / metabolism. Salivary Ducts / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983607.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


52. al Saudi N, Maartense E, Scherpenisse J, van Leeuwen AW: Watery diarrhoea: an unusual manifestation of breast cancer. Neth J Med; 2007 Dec;65(11):448-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Watery diarrhoea: an unusual manifestation of breast cancer.
  • Somatostatin-receptor scintigraphy revealed a hot spot in the left thoracic wall and subsequently, breast adenocarcinoma with neuroendocrine differentiation was diagnosed.
  • [MeSH-major] Breast Neoplasms / pathology. Diarrhea / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079568.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Gastrins; 59763-91-6 / Pancreatic Polypeptide
  •  go-up   go-down


53. Strauss BL, Bratthauer GL, Tavassoli FA: STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types. Hum Pathol; 2006 May;37(5):586-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types.
  • STAT 5a is activated through a variety of mechanisms; in the breast, this is predominantly through binding of prolactin to its receptor.
  • Previously, we showed that STAT 5a expression is decreased in atypical and malignant breast ductal epithelial cells.
  • No expression was seen in apocrine metaplasia or in other specialized breast carcinomas, such as mucinous or clear cell carcinoma.
  • Alternatively, STAT 5a expression may be related to the t(12;15)(p13;q25) chromosomal translocation, associated with certain pediatric tumors and recently demonstrated in many secretory carcinomas of the breast, which results in the expression of a tyrosine kinase through ETV6 and NTRK3 fusion.
  • Breast cancer causes significant morbidity and mortality, and, regardless of the mechanism for retention of STAT 5a expression in this uncommon variant, the examination of STAT 5a will aid our understanding of normal and abnormal breast tissues.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. STAT5 Transcription Factor / metabolism

  • Genetic Alliance. consumer health - Secretory breast carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647957.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / STAT5 Transcription Factor; 0 / STAT5A protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


54. Pavithra L, Singh S, Sreenath K, Chattopadhyay S: Tumor suppressor SMAR1 downregulates Cytokeratin 8 expression by displacing p53 from its cognate site. Int J Biochem Cell Biol; 2009 Apr;41(4):862-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evaluation of SMAR1 and Cytokeratin 8 proteins in different grades of cancer using tissue microarray point out at the inverse expression profiles of these genes (i.e. low levels of SMAR1 correlating with high expression of Cytokeratin 8) in higher grades of breast cancer.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Cell Line, Tumor. Chromatin / metabolism. DNA Damage. Down-Regulation. Humans. Immunoblotting. Immunoprecipitation. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822384.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BANP protein, human; 0 / Cell Cycle Proteins; 0 / Chromatin; 0 / DNA-Binding Proteins; 0 / Keratin-8; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


55. Zhu W, Michael CW: WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol; 2007 Jun;35(6):370-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
  • The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions can be very difficult since they all can present as tight cell clusters.
  • The aim of this study is to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic adenocarcinoma from the lung, breast and ovary in serous effusions.
  • A positive TTF1 staining supports the diagnosis of metastatic carcinoma originating from lung rather than breast, while a negative TTF1 favors the diagnosis of a breast primary.
  • Immunohistochemical studies with WT1, TTF1, and mCEA antibodies are useful in the differential diagnosis of metastatic adenocarcinomas of lung, breast, and ovary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. CA-125 Antigen / immunology. Carcinoembryonic Antigen / immunology. Nuclear Proteins / immunology. Pleural Effusion, Malignant / diagnosis. Transcription Factors / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497661.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / WT1 Proteins; 0 / thyroid nuclear factor 1
  •  go-up   go-down


56. Frago Marquínez I, Fuentes Gómez C, Maldonado Castro G, Puelles Emaldibarra N, San Miguel López de Uralde S, Echeveste Aizpurua J, Arroita González G: [Pituitary metastases in patients with prior neoplasms]. Endocrinol Nutr; 2009 May;56(5):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three cases of patients with a history of cancer (breast and lung) who presented with symptoms of headache, ophthalmoplegia, fatigue, diabetes insipidus, nausea, and vomiting.
  • The patients developed further metastases and two died soon after diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Lung Neoplasms / pathology. Pituitary Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627748.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Fujiwara A, Shibata E, Terashima H, Shishido A, Nishiki J, Yoshida K, Miyauchi K, Madachi A, Matsuura N: Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors. Breast Cancer; 2006;13(3):272-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of matrix metalloproteinase-2 (MMP-2) activity with film in situ zymography for improved cytological diagnosis of breast tumors.
  • BACKGROUND: Fine-needle aspiration (FNA) biopsy of breast tumors is a reliable diagnostic method for identifying breast carcinoma.
  • To improve the cytological diagnosis of breast tumors, we investigated the expression of active matrix metalloproteinase-2 (MMP-2), as detected by film in situ zymography (FIZ).
  • METHODS: We evaluated 34 fresh breast tumors, 25 paraffin-embedded breast tissue specimens, and a human cancer cell line (HT1080).
  • Frozen sections and aspiration cytology samples of breast cancer were incubated on gelatin-coated films for the detection of active MMP-2.
  • RESULTS: Immunohistochemistry showed that MMP-2 was expressed in cancer cells and stromal cells, but not in most benign breast lesions.
  • Gelatinolytic activity was also detected by FIZ analysis of aspiration cytology samples and frozen sections from the breast cancers, and there was a significant correlation between this gelatinolytic activity and the detection of MMP-2 expression by immunocytochemistry.
  • CONCLUSIONS: The present study demonstrated that measurement of gelatinolytic activity by FIZ analysis of aspiration cytology samples may be useful for improving the cytological diagnosis of breast tumors.
  • [MeSH-major] Breast Neoplasms / enzymology. Gelatin / metabolism. Matrix Metalloproteinase 2 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / enzymology. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / enzymology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929121.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / gelatin film; 9000-70-8 / Gelatin; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


58. Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML: Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res; 2008 Jun 15;147(2):247-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancers typically spread to regional lymph nodes once they disseminate from the primary tumor, thus adequate evaluation and treatment of the axillary lymph nodes is paramount in early stage disease.
  • Cisplatin-HA conjugates had high anti-tumor activity in vitro similar to the free drug: cisplatin-HA IC50 7 microg/mL in MCF7 and MDA-MB-231 human breast cancer cells (free cisplatin IC50 7 microg/mL).
  • CONCLUSIONS: This study demonstrates a novel intralymphatic drug delivery method in breast cancer to preferentially treat at-risk regional lymph nodes and avoid systemic toxicities.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] J Pharm Sci. 2008 Mar;97(3):1268-76 [17674407.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):866-9 [10597214.001]
  • [Cites] J Invest Dermatol. 2001 Jan;116(1):93-101 [11168803.001]
  • [Cites] Breast Cancer Res Treat. 2003;79 Suppl 1:S11-8 [12868801.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD003374 [15106201.001]
  • [Cites] Clin Exp Metastasis. 2005;22(4):351-61 [16170671.001]
  • [Cites] Anticancer Drugs. 1993 Apr;4(2):167-71 [8490195.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):53-66 [7516417.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4516-23 [7519123.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):926-30 [9291817.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20310-5 [15784621.001]
  • [Cites] Ciba Found Symp. 1989;143:41-53; discussion 53-9, 281-5 [2680348.001]
  • (PMID = 18498877.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / L30 CA136330; United States / NCI NIH HHS / CA / CA132033-01; United States / NCI NIH HHS / CA / R21 CA132033-01; United States / NCRR NIH HHS / RR / P20 RR015563; United States / NCRR NIH HHS / RR / P20 RR0155563; United States / NCRR NIH HHS / RR / P20 RR015563-086738; United States / NCI NIH HHS / CA / R21 CA132033; United States / NCI NIH HHS / CA / L30 CA136330-02; United States / NCRR NIH HHS / RR / RR015563-086738
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9004-61-9 / Hyaluronic Acid; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS52882; NLM/ PMC2430723
  •  go-up   go-down


59. Yasuda M, Akiyama N, Miyamoto S, Warabi M, Takahama Y, Kitamura M, Yakushiji F, Kinoshita H: Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma. Pituitary; 2010;13(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though we conducted systemic investigations including chest and abdomen enhanced computer tomography, transbronchial lung biopsy, and bone marrow biopsy, the diagnosis was not confirmed.
  • Inadvertently, a breast cancer was found, and the surgical specimen proved that the patient had double cancer-adenocarcinoma and IVLBCL.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cranial Nerves / physiology. Cranial Nerves / physiopathology. Female. Humans. Neoplasms, Second Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Acta Neuropathol. 1999 Mar;97(3):311-6 [10090680.001]
  • [Cites] Endocr J. 2005 Oct;52(5):543-9 [16284431.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):112-23 [2420221.001]
  • [Cites] Am J Med. 1999 Aug;107(2):169-76 [10460050.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3168-73 [17577023.001]
  • [Cites] Acta Neurochir (Wien). 2008 Aug;150(8):833-6 [18574548.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1470-6 [11297569.001]
  • [Cites] Pituitary. 2011 Jun;14 (2):194-7 [19123039.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1525-7 [18053461.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi [10207686.001]
  • [Cites] Australas Radiol. 2000 Feb;44(1):112-4 [10761271.001]
  • [Cites] Am J Clin Pathol. 1979 Jun;71(6):724-7 [377944.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):46-9 [19229666.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] Pituitary. 2009;12(1):76-9 [18205050.001]
  • [Cites] Am J Med. 1996 Nov;101(5):563-4 [8948282.001]
  • [Cites] Endocr Pract. 2003 Jul-Aug;9(4):296-300 [14561574.001]
  • [Cites] Wien Klin Wochenschr. 2006 Jul;118(13-14):422-5 [16865648.001]
  • [Cites] Am J Med Sci. 2004 Aug;328(2):124-8 [15311173.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):231-2 [10706771.001]
  • [Cites] Histopathology. 1997 Aug;31(2):161-6 [9279568.001]
  • [Cites] Pituitary. 2000 May;2(4):283-7 [11081150.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):335-341 [12114795.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):236-44 [18081700.001]
  • [Cites] J R Soc Med. 1997 May;90(5):274-5 [9204025.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):236-9 [15224358.001]
  • [Cites] Folia Neuropathol. 2007;45(3):144-8 [17849366.001]
  • [Cites] Rinsho Shinkeigaku. 1999 Nov;39(11):1160-3 [10689943.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2000 Jan;38(1):34-8 [10723949.001]
  • [Cites] No To Shinkei. 1998 Dec;50(12):1133-41 [9989361.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):88-91 [8225384.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):861-8 [8078533.001]
  • [Cites] Dermatology. 2004;209(2):135-7 [15316168.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):130-3 [11216706.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):246-50 [12480233.001]
  • [Cites] No Shinkei Geka. 1998 Jan;26(1):53-8 [9488992.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1611-6 [15370213.001]
  • [Cites] Medicine (Baltimore). 1999 Jul;78(4):236-69 [10424206.001]
  • [Cites] Med Pediatr Oncol. 2001 Mar;36(3):392-5 [11241445.001]
  • [Cites] Cas Lek Cesk. 2008;147(11):569-73 [19097361.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1738-45 [8156502.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):227-31 [15072472.001]
  • [Cites] Blood. 2007 Jan 15;109(2):478-85 [16985183.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3189-95 [18506023.001]
  • [Cites] Endocrine. 2008 Aug-Dec;34(1-3):11-6 [18937075.001]
  • [Cites] J Clin Neurosci. 2008 Oct;15(10):1148-51 [18653342.001]
  • (PMID = 19707877.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


60. Guilford P, Humar B, Blair V: Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer; 2010 Mar;13(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hereditary diffuse gastric cancer (HDGC) is the only known cancer syndrome that is dominated by gastric adenocarcinoma.
  • Mutation carriers have a more than 70% lifetime risk of developing DGC and an elevated risk of lobular breast cancer.


61. Sis B, Sarioglu S, Sokmen S, Sakar M, Kupelioglu A, Fuzun M: Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma. J Clin Pathol; 2005 Jan;58(1):32-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Image Processing, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2497-503 [10811131.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):1010-6 [8335394.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):512-21 [8112888.001]
  • [Cites] Physiol Rev. 1996 Jan;76(1):69-125 [8592733.001]
  • [Cites] Pathol Res Pract. 1996 Jul;192(7):712-7 [8880872.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):497-507 [9033266.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 Apr;106(4):271-8 [9109715.001]
  • [Cites] Pathol Int. 1998 Jan;48(1):1-9 [9589457.001]
  • [Cites] Lab Invest. 1998 May;78(5):511-22 [9605176.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):629-36 [10225455.001]
  • [Cites] Auris Nasus Larynx. 2004 Dec;31(4):417-24 [15571917.001]
  • [Cites] J Clin Pathol. 2001 Jun;54(6):461-5 [11376020.001]
  • [Cites] J Hepatol. 2001 May;34(5):740-7 [11434621.001]
  • [Cites] Histopathology. 2001 Oct;39(4):416-25 [11683944.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4341-8 [11908689.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):55-60 [11918083.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3298-307 [12036948.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Nov;34(11):1401-14 [12200035.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2546-54 [12467069.001]
  • [Cites] J Am Soc Nephrol. 2003 Jun;14(6):1662-8 [12761269.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):870-6 [12942120.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(2):137-47 [14572156.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4):343-8 [14606634.001]
  • [Cites] Tohoku J Exp Med. 2003 Oct;201(2):67-73 [14626507.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1663-7 [3815362.001]
  • [Cites] J Clin Pathol. 1989 Feb;42(2):162-6 [2921357.001]
  • [Cites] Int J Cancer. 1993 Jan 2;53(1):62-9 [7677932.001]
  • [Cites] Int J Dev Biol. 1993 Mar;37(1):203-11 [8507562.001]
  • (PMID = 15623479.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770537
  •  go-up   go-down


62. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res; 2006 Feb 15;66(4):2153-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of Foxm1 is found in a variety of distinct human cancers including hepatocellular carcinomas, intrahepatic cholangiocarcinomas, basal cell carcinomas, ductal breast carcinomas, and anaplastic astrocytomas and glioblastomas.
  • Transient transfection experiments with A549 lung adenocarcinoma cells show that depletion of Foxm1 levels by short interfering RNA caused diminished DNA replication and mitosis and reduced anchorage-independent growth of cell colonies on soft agar.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Alleles. Animals. Cell Adhesion. Cell Growth Processes / physiology. Cyclin A / biosynthesis. Cyclin A / genetics. Cyclin A2. Cyclin B / biosynthesis. Cyclin B / genetics. Cyclin B1. DNA Replication. DNA, Neoplasm / biosynthesis. Gene Deletion. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Mitosis. RNA, Small Interfering / genetics. Urethane


63. Gdovinova Z, Feketeova E, Szilasiova J, Havlikova E, Banik P: Meningeal carcinomatosis as the first manifestation of malignant carcinomatosis. Bratisl Lek Listy; 2009;110(8):490-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In two cases, adenocarcinoma ventriculi was found, in other one, the markers of the gastrointestinal tract malignancy were highly positive but malignity was not found, and in the last one, there was a known breast carcinoma.
  • The diagnosis of MC requires the finding of malignant cells in the cerebrospinal fluid, but sometimes several lumbar punctures are required to establish the diagnosis, and also MRI with gadolinium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19750988.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


64. Akatsu T, Kameyama K, Kawachi S, Tanabe M, Aiura K, Wakabayashi G, Ueda M, Shimazu M, Kitajima M: Gallbladder carcinoma with osteoclast-like giant cells. J Gastroenterol; 2006 Jan;41(1):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These neoplasms are most frequently reported in the breast and pancreas.
  • Further studies are required to clearly define the prognostic significance of these giant cells in gallbladder cancer and the differences between adenosquamous carcinoma with OGCs and other gallbladder carcinomas (such as adenocarcinoma and squamous cell carcinoma) with those cells.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):453-9 [7726143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4 [2169622.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Breast. 2001 Jun;10(3):231-6 [14965590.001]
  • [Cites] Endocrinology. 1989 Jul;125(1):20-7 [2544401.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1678-81 [10364044.001]
  • [Cites] Cancer. 1988 May 1;61(9):1872-9 [2451557.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1177-9 [7611227.001]
  • (PMID = 16501862.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Matsuzuka T, Rachakatla RS, Doi C, Maurya DK, Ohta N, Kawabata A, Pyle MM, Pickel L, Reischman J, Marini F, Troyer D, Tamura M: Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer; 2010 Oct;70(1):28-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the anti-cancer effect of IFN-beta gene-transfected hUCMSCs (IFN-beta-hUCMSCs) on cells derived from bronchioloalveolar carcinoma, a subset of lung adenocarcinoma that is difficult to treat.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Cord Blood Stem Cell Transplantation / methods. Interferon-beta / biosynthesis. Lung Neoplasms / surgery. Mesenchymal Stromal Cells / physiology. Umbilical Cord / cytology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] J Natl Cancer Inst. 1992 Aug 5;84(15):1185-90 [1378904.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):526-30 [2494120.001]
  • [Cites] J Interferon Cytokine Res. 1996 Oct;16(10):759-64 [8910759.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13862-7 [9391118.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3908-13 [9520466.001]
  • [Cites] Hum Gene Ther. 1998 Sep 20;9(14):1983-93 [9759926.001]
  • [Cites] Cancer Immunol Immunother. 1998 Nov;47(3):143-8 [9829839.001]
  • [Cites] Hum Gene Ther. 1998 Dec 10;9(18):2699-708 [9874268.001]
  • [Cites] Exp Cell Res. 1999 Feb 25;247(1):133-41 [10047455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10711-6 [10485891.001]
  • [Cites] Gene Ther. 1999 Sep;6(9):1626-33 [10490773.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 [15523088.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3307-18 [15833864.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8379-87 [16166316.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):781-92 [16223852.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jul;3(7):388-98 [16826219.001]
  • [Cites] Stem Cell Rev. 2006;2(2):155-62 [17237554.001]
  • [Cites] Cancer Gene Ther. 2007 Oct;14(10):828-35 [17599089.001]
  • [Cites] Blood. 2008 Jan 1;111(1):430-8 [17909081.001]
  • [Cites] Stem Cells. 2008 Nov;26(11):2865-74 [18703664.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1815-20 [19244122.001]
  • [Cites] Cancer Lett. 2009 Jul 18;280(1):31-7 [19285791.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Interferon Cytokine Res. 2000 Oct;20(10):857-66 [11054273.001]
  • [Cites] Breast Cancer Res. 2000;2(1):32-44 [11250691.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1821-31 [11410525.001]
  • [Cites] Cancer Pract. 2002 Jan-Feb;10(1):53-6 [11866711.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1258-70 [11948141.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3603-8 [12097260.001]
  • [Cites] Mol Cancer Ther. 2002 Aug;1(10):777-83 [12492110.001]
  • [Cites] Stem Cells. 2003;21(1):50-60 [12529551.001]
  • [Cites] Cancer Gene Ther. 2003 Jul;10(7):549-58 [12833135.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2508-18 [12839017.001]
  • [Cites] J Interferon Cytokine Res. 2004 Apr;24(4):231-43 [15144569.001]
  • [Cites] Gene Ther. 2004 Jul;11(14):1155-64 [15141157.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Interferon Cytokine Res. 1996 Apr;16(4):275-81 [9162520.001]
  • (PMID = 20138387.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR015563; United States / NCRR NIH HHS / RR / P20 RR015563; United States / NCRR NIH HHS / RR / P20 RR016475; United States / NCRR NIH HHS / RR / P20 RR017686
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 77238-31-4 / Interferon-beta
  • [Other-IDs] NLM/ NIHMS171227; NLM/ PMC2930041
  •  go-up   go-down


66. Bollmann J, Ortmann O, Treeck O: Expression of differentiation-associated gene icb-1 is estrogen-responsive in ovarian and breast cancer cell lines. J Steroid Biochem Mol Biol; 2008 Mar;109(1-2):16-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of differentiation-associated gene icb-1 is estrogen-responsive in ovarian and breast cancer cell lines.
  • icb-1 (C1orf38) is a human gene initially described by our group to be upregulated during in vitro differentiation processes of endometrial adenocarcinoma and leukemia cells triggered by different stimuli.
  • Given that estrogens are known to regulate cellular differentiation processes of hormone-dependent tissues, we studied whether expression of icb-1 would be regulated by 17-beta (beta) estradiol in breast and ovarian cancer cells.
  • As examined by means of real time PCR, treatment with 17-beta estradiol for at least 24h resulted in a significant increase of icb-1 transcript levels in ERalpha-positive MCF-7 breast cancer and OVCAR-3 ovarian cancer cells, but not in ERalpha-negative SK-BR-3 and SK-OV-3 cells.
  • The results of this study demonstrate that transcript levels of differentiation-associated gene icb-1 are estrogen-responsive in breast and ovarian cancer cells in an ERalpha-dependent manner.
  • [MeSH-major] Breast Neoplasms / genetics. Estradiol / pharmacology. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206364.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C1orf38 protein, human; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 4TI98Z838E / Estradiol
  •  go-up   go-down


67. Kamitani K, Ono M, Toyoshima S, Mitsuyama S, Anan K, Ikeda Y: Isoechoic axillary lymph node metastases of mucinous carcinoma of the breast: a case report. Breast Cancer; 2006;13(4):382-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoechoic axillary lymph node metastases of mucinous carcinoma of the breast: a case report.
  • We report a case of isoechoic axillary lymph node metastasis of mucinous carcinoma (so-called pure mucinous carcinoma) of the breast.
  • A 47-year-old premenopausal woman was referred to our hospital with a 2 years history of mass and distortion of her left breast and with recent worsening of her symptoms.
  • Based on a preoperative diagnosis of mucinous carcinoma of the left breast with left axillary lymph nodes metastases, left mastectomy and left axillary nodal dissection were performed.
  • Although lymph node metastasis of mucinous carcinoma of the breast is rare, ultrasonographers should perform careful scanning when the primary breast mass is suspicious for mucinous carcinoma, because lymph node metastases of mucinous carcinoma can be more indistinct and difficult to detect than those of other types of breast cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Axilla / pathology. Breast Neoplasms / pathology. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146168.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Blumencranz P, Whitworth PW, Deck K, Rosenberg A, Reintgen D, Beitsch P, Chagpar A, Julian T, Saha S, Mamounas E, Giuliano A, Simmons R: Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg; 2007 Oct;194(4):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors.
  • BACKGROUND: When sentinel node dissection reveals breast cancer metastasis, completion axillary lymph node dissection is ideally performed during the same operation.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Diagnostic Errors. Sentinel Lymph Node Biopsy. Specimen Handling / standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826050.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


69. Saito H, Tsujitani S, Ikeguchi M: Clinical significance of skip metastasis in patients with gastric cancer. Gastric Cancer; 2007;10(2):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / mortality. Carcinoma, Signet Ring Cell / secondary. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2002 Mar;26(3):318-22 [11865368.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1435-7 [12390388.001]
  • [Cites] Gastric Cancer. 2004;7(3):140-8 [15449201.001]
  • [Cites] Gastric Cancer. 1999 Aug;2(2):95-100 [11957080.001]
  • [Cites] Lancet. 1997 Jun 28;349(9069):1864-7 [9217757.001]
  • [Cites] Br J Surg. 2002 May;89(5):604-8 [11972551.001]
  • [Cites] J Surg Oncol. 2003 Apr;82(4):256-60 [12672010.001]
  • [Cites] Surgery. 2001 Jun;129(6):684-91 [11391366.001]
  • [Cites] ANZ J Surg. 2005 Aug;75(8):645-9 [16076325.001]
  • [Cites] Breast Cancer Res Treat. 1991 Nov;19(3):277-81 [1663806.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] J Am Coll Surg. 1999 Aug;189(2):183-94 [10437841.001]
  • [Cites] Surg Today. 1994;24(10):870-5 [7894183.001]
  • [Cites] J Am Coll Surg. 1999 Aug;189(2):214-23 [10437845.001]
  • [Cites] Surg Gynecol Obstet. 1986 Mar;162(3):229-34 [3952614.001]
  • [Cites] N Engl J Med. 1998 Oct 1 ;339(14 ):941-6 [9753708.001]
  • [Cites] Gut. 1994 Oct;35(10):1368-71 [7959188.001]
  • [Cites] J Clin Oncol. 1999 Mar;17 (3):976-83 [10071292.001]
  • (PMID = 17577617.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Park JM, Kim DS, Oh SH, Kwon YS, Lee KH: A case of esophageal adenocarcinoma metastasized to the scalp. Ann Dermatol; 2009 May;21(2):164-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of esophageal adenocarcinoma metastasized to the scalp.
  • Lung, breast, and colorectal cancers are common primary tumors that metastasize to the skin; cutaneous metastasis usually occurs on the chest wall and abdomen as asymptomatic nodular patterns.
  • Esophageal cancer is not nearly as common as breast, lung, and colorectal cancers, and esophageal cancer rarely metastasizes to the skin.
  • Herein, we describe a case of metastatic skin cancer that originated from esophageal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2007 Jun;22(6):908-12 [17565647.001]
  • [Cites] Gastroenterologist. 1997 Dec;5(4):278-94 [9436004.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • [Cites] J Am Acad Dermatol. 1990 Jan;22(1):19-26 [2298962.001]
  • [Cites] J Cutan Pathol. 2004 Jul;31(6):419-30 [15186430.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] J Cutan Pathol. 2001 Sep;28(8):425-31 [11493381.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1120-5 [8630886.001]
  • [Cites] J Am Acad Dermatol. 1995 Aug;33(2 Pt 1):161-82; quiz 183-6 [7622642.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):228-36 [8335743.001]
  • [Cites] J Am Acad Dermatol. 1993 Jan;28(1):1-13 [8425947.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Ann Dermatol Venereol. 2001 Dec;128(12):1310-5 [11908133.001]
  • [Cites] J Clin Ultrasound. 2007 Jun;35(5):289-92 [17366561.001]
  • (PMID = 20523777.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2861207
  • [Keywords] NOTNLM ; Adenocarcinoma / Esophagus / Metastasis / Scalp
  •  go-up   go-down


71. Kapila K, Pathan SK, Al-Mosawy FA, George SS, Haji BE, Al-Ayadhy B: Fine needle aspiration cytology of breast masses in children and adolescents: experience with 1404 aspirates. Acta Cytol; 2008 Nov-Dec;52(6):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of breast masses in children and adolescents: experience with 1404 aspirates.
  • OBJECTIVE: To study the distribution and efficacy of fine needle aspiration cytology (FNAC) in the diagnosis of breast lesions in pediatric and adolescent patients.
  • STUDY DESIGN: From January 1993 to December 2006, the cytology reports of 1404 breast aspirates (178 males and 1226 females) performed on children and adolescents (ranging from 1 to 21 years) were reviewed.
  • There were 3 cases of malignancy (2 adenocarcinoma and 1 non-Hodgkin's lymphoma).
  • Only 3% of the male breast aspirates provided a diagnostic challenge, while 89% of them showed benign ductal cells.
  • CONCLUSION: FNAC of children and adolescent breast masses is helpful and can reduce the need for open surgery to prevent later deformity.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Child. Child, Preschool. Female. Humans. Hyperplasia / pathology. Immunoenzyme Techniques. Infant. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068671.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S: Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res; 2009;11(4):R59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
  • INTRODUCTION: The role of circulating tumor cells (CTCs) in blood of primary breast cancer patients is still under investigation.
  • METHODS: Blood of 431 patients with primary breast cancer were analyzed for EpCAM, MUC1 and HER2 transcripts with the AdnaTest BreastCancer (AdnaGen AG, Germany).
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Bone Marrow / pathology. Bone Marrow Neoplasms / secondary. Breast Neoplasms / pathology. Neoplasm Proteins / analysis. Neoplastic Cells, Circulating / chemistry

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2171-5 [16158960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):80-6 [10623696.001]
  • [Cites] N Engl J Med. 2000 Feb 24;342(8):525-33 [10684910.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1890-5 [11280743.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1582-9 [11410494.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4102-8 [11751508.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):984-90 [14601059.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):620-7 [14696130.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1392-400 [14977842.001]
  • [Cites] Surgery. 2004 Apr;135(4):419-26 [15041966.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):631-6 [15151202.001]
  • [Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5342-8 [15328170.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4712-5 [1873815.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1419-24 [7688814.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8 [8931609.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):854-61 [9291805.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):750-6 [9495244.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Sep;23(3):465-8 [15595637.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8152-62 [15623589.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1154-9 [15709183.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3678-85 [15897564.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1803-10 [16033103.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1503-7 [15980160.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]
  • [Cites] Recent Results Cancer Res. 2003;162:141-7 [12790328.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2013-9 [16287086.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):672-80 [16495933.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1715-20 [16551854.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(1):91-6 [16319975.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(2):179-84 [16552629.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 19;98(14):1011-4 [16849684.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3756-62 [16769987.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):885-92 [16874814.001]
  • [Cites] Mol Biotechnol. 2006 Sep;34(1):15-27 [16943567.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5615-21 [17020963.001]
  • [Cites] Clin Breast Cancer. 2007 Feb;7(6):471-9 [17386124.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3A):1337-41 [17593628.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5194-202 [17954712.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R74 [17963511.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):55-60 [18197007.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3306-11 [18519757.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2726-36 [19056036.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R76 [18793387.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2177-84 [19332733.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jun;115(3):581-90 [18679793.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(2):227-33 [18791864.001]
  • [Cites] Breast Cancer Res Treat. 2009 Dec;118(3):455-68 [19115104.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):276-84 [19953098.001]
  • [Cites] Cytotherapy. 1999;1(5):377-88 [20426539.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3404-12 [12177100.001]
  • [CommentIn] Breast Cancer Res. 2010;12(3):402 [20584343.001]
  • [CommentIn] Breast Cancer Res. 2009;11(5):109 [19833005.001]
  • (PMID = 19664291.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Estrogens; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; 68238-35-7 / Keratins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2750121
  •  go-up   go-down


73. de Medina P, Payré B, Boubekeur N, Bertrand-Michel J, Tercé F, Silvente-Poirot S, Poirot M: Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ; 2009 Oct;16(10):1372-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism.
  • We have recently reported that cytostatic concentrations of the microsomal antiestrogen-binding site (AEBS) ligands, such as PBPE (N-pyrrolidino-(phenylmethyphenoxy)-ethanamine,HCl) and tamoxifen, induced differentiation characteristics in breast cancer cells through the accumulation of post-lanosterol intermediates of cholesterol biosynthesis.
  • We show here that exposure of MCF-7 (human breast adenocarcinoma cell line) cells to higher concentrations of AEBS ligands triggered active cell death and macroautophagy.
  • Collectively, these data support a therapeutic potential for selective AEBS ligands in breast cancer management and shows a mechanism that explains the induction of autophagy in MCF-7 cells by tamoxifen and other selective estrogen receptor modulators.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Apoptosis. Autophagy. Breast Neoplasms / metabolism. Cholesterol / metabolism. Estrogen Receptor Modulators / pharmacology. Ethylamines / toxicity. Pyrrolidines / toxicity. Tamoxifen / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521424.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 0 / Ethylamines; 0 / Ligands; 0 / N-pyrrolidino-(phenylmethyphenoxy)-ethanamine; 0 / Pyrrolidines; 0 / Reactive Oxygen Species; 094ZI81Y45 / Tamoxifen; 1406-18-4 / Vitamin E; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


74. Chatterjee M, Balaraman K, McDermott P: Metastatic breast carcinoma discovered in a dentigerous cyst - a case report. Br Dent J; 2006 Sep 23;201(6):349-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast carcinoma discovered in a dentigerous cyst - a case report.
  • This paper reports a patient with a history of breast cancer, who presented with altered sensation to the right lower lip and chin.
  • The subsequent histopathology report concluded that the cyst contained metastatic adenocarcinoma from a primary breast tumour.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Dentigerous Cyst / pathology. Mandibular Neoplasms / secondary. Paresthesia / etiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990884.001).
  • [ISSN] 0007-0610
  • [Journal-full-title] British dental journal
  • [ISO-abbreviation] Br Dent J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Maounis N, Chorti M, Legaki S, Ellina E, Emmanouilidou A, Demonakou M, Tsiafaki X: Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature. Diagn Pathol; 2010;5:82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature.
  • Breast metastasis from extra-mammary malignancy is rare.
  • The primary malignancies most commonly metastasizing to the breast are leukemia-lymphoma, and malignant melanoma.
  • We present a case of metastasis to the breast from a pulmonary adenocarcinoma, with extensive micropapillary component, diagnosed concomitantly with the primary tumor.
  • Additionally, on physical examination a poorly defined mass was noted in the upper outer quadrant of the left breast.
  • The patient underwent bronchoscopy, excisional breast biopsy and medical thoracoscopy.
  • By cytology, histology and immunohistochemistry primary lung adenocarcinoma with metastasis to the breast and parietal pleura was diagnosed.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Carcinoma, Papillary / secondary. Lung Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Mammography. Predictive Value of Tests. Thoracoscopy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ultrasound Med. 2000 Apr;19(4):257-62 [10759349.001]
  • [Cites] J Surg Oncol. 2010 Feb 1;101(2):137-40 [20082359.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2259-66 [11745279.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):353-61 [11956814.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1825-6 [12820464.001]
  • [Cites] Med Oncol. 2003;20(2):181-4 [12835522.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):137-41 [19875957.001]
  • [Cites] Mod Pathol. 2010 May;23(5):654-61 [20173733.001]
  • [Cites] Diagn Pathol. 2010;5:37 [20565809.001]
  • [Cites] Am Surg. 2004 Apr;70(4):287-90 [15098776.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Acta Oncol. 1992;31(4):479 [1632985.001]
  • [Cites] South Med J. 1997 Oct;90(10):1063-4 [9347825.001]
  • [Cites] Australas Radiol. 1998 Feb;42(1):16-9 [9509597.001]
  • [Cites] Acta Chir Belg. 2005 Feb;105(1):59-61 [15790204.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):366-7 [16848849.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Australas Radiol. 2007 Apr;51(2):133-8 [17419856.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):731-7 [17582626.001]
  • [Cites] South Med J. 2007 Aug;100(8):850-1 [17715476.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1333-41 [18042689.001]
  • [Cites] Arch Pathol Lab Med. 2008 Feb;132(2):239-43 [18251583.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):426-32 [18300807.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):682-7 [18048381.001]
  • [Cites] Pathology. 2008 Jun;40(4):345-51 [18446623.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1299-301 [18505069.001]
  • [Cites] APMIS. 2009 Oct;117(10):762-7 [19775345.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2009 Oct;57(10):534-9 [19830516.001]
  • [Cites] Eur Radiol. 2001;11(9):1659-65 [11511887.001]
  • (PMID = 21167048.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] Adenocarcinoma of lung
  • [Other-IDs] NLM/ PMC3018363
  •  go-up   go-down


76. Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N: Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer; 2007 Nov 1;110(9):1945-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Diseases / chemically induced. Colonic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853393.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004931
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Greco O, Powell TM, Marples B, Joiner MC, Scott SD: Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin. Cancer Gene Ther; 2005 Jul;12(7):655-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human MCF-7 breast adenocarcinoma and U373-MG glioblastoma cells were transfected with plasmids containing CArG promoters controlling the expression of the green fluorescent protein (GFP).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / therapy. Breast Neoplasms / therapy. DNA-Binding Proteins / genetics. Gene Expression Regulation / drug effects. Genetic Therapy / methods. Genetic Vectors. Immediate-Early Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / therapy. Antiviral Agents / therapeutic use. Apoptosis. Cisplatin / pharmacology. Combined Modality Therapy. Doxorubicin / pharmacology. Early Growth Response Protein 1. Ganciclovir / metabolism. Gene Transfer Techniques. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / therapy. Green Fluorescent Proteins / metabolism. Humans. Neutrons. Promoter Regions, Genetic. Radiation-Sensitizing Agents / therapeutic use. Response Elements / genetics. Simplexvirus / enzymology. Simplexvirus / genetics. Thymidine Kinase / genetics. Thymidine Kinase / metabolism. Tumor Cells, Cultured. Zinc Fingers

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15818381.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / DNA-Binding Proteins; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Immediate-Early Proteins; 0 / Radiation-Sensitizing Agents; 0 / Transcription Factors; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 80168379AG / Doxorubicin; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


78. Xie D, Sham JS, Zeng WF, Lin HL, Bi J, Che LH, Hu L, Zeng YX, Guan XY: Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol; 2005 Jul;36(7):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIB1, a member of the steroid receptor coactivator 1 family, has been cloned on 20q12 and is a candidate oncogene in human breast cancer.
  • [MeSH-major] Acetyltransferases / metabolism. Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Oncogene Proteins / metabolism. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084947.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Oncogene Proteins; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA3 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


79. Gomez-Monterrey I, Campiglia P, Carotenuto A, Stiuso P, Bertamino A, Sala M, Aquino C, Grieco P, Morello S, Pinto A, Ianelli P, Novellino E: Spiro[(dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)]-based cytotoxic agents: structure-activity relationship studies on the substituent at N4-position of the diketopiperazine domain. J Med Chem; 2008 May 22;51(10):2924-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro activity was evaluated against the MCF-7 human breast carcinoma and SW 620 human colon carcinoma cell lines.
  • These compounds, in both racemic and pure enantiomeric forms, showed also a high efficacy in cell lines resistant to doxorubicin (MCF-7/Dx) and in cell lines that were highly resistant to treatment with doxorubicin, such as HEK-293 (kidney), M-14 (melanoma), and HeLa (cervical adenocarcinoma) human cell lines.
  • In addition, the effects on growth and cell cycle progression in CaCo-2 cell line (colon adenocarcinoma) and DNA-binding properties were investigated.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429610.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-((2-N,N-dimethyl)amino)ethylspiro((dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno(2,3-b)naphtho-4',9'-dione)); 0 / 4-(2-pyrrolidine)ethylspiro((dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno(2,3-b)naphtho-4',9'-dione)); 0 / Antineoplastic Agents; 0 / Diketopiperazines; 0 / Naphthoquinones; 0 / Pyrazines; 9007-49-2 / DNA
  •  go-up   go-down


80. Tew WP, Kelsen DP, Ilson DH: Targeted therapies for esophageal cancer. Oncologist; 2005 Sep;10(8):590-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, gastric and esophageal cancers together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 2000-more than lung, breast, or colorectal cancer.
  • Although esophageal squamous cell carcinoma cases have steadily declined, the incidence of gastroesophageal junction adenocarcinoma has increased 4%-10% per year among U.S. men since 1976, more rapidly than for any other cancer type, and parallels rises in population trends in obesity and reflux disease.
  • This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177283.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 128
  •  go-up   go-down


81. Ryan AJ, Napoletano S, Fitzpatrick PA, Currid CA, O'Sullivan NC, Harmey JH: Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer. Br J Cancer; 2009 Jul 21;101(2):278-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.
  • BACKGROUND: Insulin-like growth factor 1 (IGF1) promotes breast cancer and disease progression.
  • 4T1.2 mouse mammary adenocarcinoma cells transfected with empty vector, vector expressing wild-type IGFBP4 or vector expressing dBP4 were implanted in the mammary fat pad of BALB/c mice and tumour growth was assessed.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Apoptosis / physiology. Cell Growth Processes / physiology. Disease Models, Animal. Humans. Insulin-Like Growth Factor I / metabolism. Insulin-Like Growth Factor I / pharmacology. Mice. Mice, Inbred BALB C. Mutation. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Pregnancy-Associated Plasma Protein-A / biosynthesis. Pregnancy-Associated Plasma Protein-A / metabolism. Receptor, IGF Type 1 / biosynthesis. Recombinant Proteins / pharmacology. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1993;29A(4):492-7 [8435198.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2655-61 [7679099.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1727-30 [8467486.001]
  • [Cites] Endocrinology. 1993 Nov;133(5):2362-70 [7691588.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):104-10 [7530254.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4395-400 [7533161.001]
  • [Cites] Endocr Rev. 1995 Apr;16(2):143-63 [7540132.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Mar;8(1):45-62 [9174662.001]
  • [Cites] Endocrine. 1997 Aug;7(1):33-6 [9449028.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Endocrinology. 1998 Aug;139(8):3456-64 [9681496.001]
  • [Cites] Endocr J. 1998 Apr;45 Suppl:S1-8 [9790222.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3149-53 [10077652.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):163-70 [10411109.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):698-706 [15541345.001]
  • [Cites] J Ocul Pharmacol Ther. 2004 Dec;20(6):554-62 [15684814.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7245-52 [16849573.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9787 [17018641.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):883-8 [17332927.001]
  • [Cites] Endocrinology. 2007 Oct;148(10):5002-10 [17640990.001]
  • [Cites] Endocr Rev. 1995 Feb;16(1):3-34 [7758431.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31128-33 [10913121.001]
  • [Cites] Growth Horm IGF Res. 2000 Dec;10(6):360-6 [11161967.001]
  • [Cites] Endocrinology. 2001 Jun;142(6):2641-8 [11356715.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2960-8 [11358513.001]
  • [Cites] FEBS Lett. 2001 Aug 24;504(1-2):36-40 [11522292.001]
  • [Cites] Nature. 2001 Dec 13;414(6865):799-806 [11742412.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21285-90 [11923290.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):415-22 [12216068.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1349-53 [12516969.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Blood. 2004 Jan 15;103(2):601-6 [14512300.001]
  • [Cites] Development. 2004 Mar;131(5):1187-94 [14973274.001]
  • [Cites] Endocr Res. 2004 Feb;30(1):47-59 [15098919.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2382-9 [15126567.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):228-35 [2579017.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Oct 14;156(1):199-204 [2972283.001]
  • [Cites] J Clin Invest. 1993 Mar;91(3):1129-37 [7680662.001]
  • (PMID = 19536088.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 4; 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor A; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.10.1 / Receptor, IGF Type 1; EC 3.4.24.- / Pregnancy-Associated Plasma Protein-A
  • [Other-IDs] NLM/ PMC2720214
  •  go-up   go-down


82. Mecca P, Busam K: Primary male neuroendocrine adenocarcinoma involving the nipple simulating Merkel cell carcinoma - a diagnostic pitfall. J Cutan Pathol; 2008 Feb;35(2):207-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary male neuroendocrine adenocarcinoma involving the nipple simulating Merkel cell carcinoma - a diagnostic pitfall.
  • Male breast cancer is a rare entity accounting for < 1% of all breast cancer cases in the United States, but with a rate that has been rising over the last 25 years.
  • Likewise, true neuroendocrine carcinoma of the breast, defined as > 50% of tumor cells staining for either chromogranin or synaptophysin, is not a common entity, usually occurring in older women.
  • To the best of our knowledge, although reported in the male breast, no case of primary nipple neuroendocrine carcinoma in a male patient has been reported in the literature.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Carcinoma, Merkel Cell / pathology. Carcinoma, Neuroendocrine / pathology. Diagnostic Errors. Nipples / pathology

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190447.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


83. Lovett DH, Cheng S, Cape L, Pollock AS, Mertens PR: YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun; 2010 Jul 30;398(3):482-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis.
  • YB-1 is linked to poor prognosis in breast carcinoma and is a strong predictor of relapse and disease-specific survival.
  • Non-invasive MCF-7 breast adenocarcinoma cells were transfected with YB-1/EGFP.
  • We conclude that YB-1 contributes to the development of an invasive, metastatic breast carcinoma phenotype by enhanced presentation of MT1-MMP at the sites of cellular invasion.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] EMBO J. 2001 Oct 1;20(19):5491-502 [11574481.001]
  • [Cites] RNA Biol. 2009 Jan-Mar;6(1):59-64 [19098458.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18241-8 [12604611.001]
  • [Cites] Bioessays. 2003 Jul;25(7):691-8 [12815724.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] J Cell Sci. 2003 Oct 1;116(Pt 19):3905-16 [12915589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(19):7322-6 [3174636.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15074-83 [8663054.001]
  • [Cites] Nat Med. 1997 Apr;3(4):447-50 [9095180.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22905-12 [9278454.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32957-65 [9830047.001]
  • [Cites] J Cell Sci. 1999 Oct;112 ( Pt 20):3487-96 [10504297.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7702-11 [15615704.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4078-87 [15899797.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30564-73 [15985431.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4872-9 [16651443.001]
  • [Cites] EMBO J. 2007 Mar 21;26(6):1499-510 [17332756.001]
  • [Cites] BMC Biochem. 2008;9:23 [18793384.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R86 [18925950.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • (PMID = 20599698.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R56 DK039776; United States / NIDDK NIH HHS / DK / DK039776-21; United States / NIDDK NIH HHS / DK / DK059383-05; United States / NIDDK NIH HHS / DK / R01 DK039776-21; United States / NIDDK NIH HHS / DK / K08 DK059383-05; United States / NIDDK NIH HHS / DK / R01 DK039776; United States / NIDDK NIH HHS / DK / R01-DK39776; United States / NIDDK NIH HHS / DK / KO8-DK59381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Y-Box-Binding Protein 1; 0 / YBX1 protein, human; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS225358; NLM/ PMC2925540
  •  go-up   go-down


84. Paciello O, Borzacchiello G, Varricchio E, Papparella S: Expression of peroxisome proliferator-activated receptor gamma (PPAR-gamma) in canine nasal carcinomas. J Vet Med A Physiol Pathol Clin Med; 2007 Oct;54(8):406-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PPAR-gamma is expressed in multiple normal and neoplastic tissues, such as the breast, colon, lung, ovary and placenta.
  • In addition to adipogenic and anti-inflammatory effects, PPAR-gamma activation has been shown to be anti-proliferative by its differentiation-promoting effect, suggesting that activation of PPAR-gamma may be useful in slowing or arresting the proliferation of de-differentiated tumour cells.
  • [MeSH-major] Adenocarcinoma / veterinary. Carcinoma / veterinary. Dog Diseases / metabolism. Gene Expression Regulation, Neoplastic. Nose Neoplasms / veterinary. PPAR gamma / metabolism

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877580.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / PPAR gamma
  •  go-up   go-down


85. Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA: Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol; 2010 Jan;194(1):266-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Biopsy, Needle / methods. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):13-9 [11759824.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1155-66 [12006532.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2960-71 [12784330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):296-9 [3791214.001]
  • [Cites] Clin Imaging. 1997 Mar-Apr;21(2):107-10 [9095385.001]
  • [Cites] Chest. 1997 Aug;112(2):423-5 [9266878.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] Acta Cytol. 2005 Sep-Oct;49(5):554-9 [16334036.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4764-74 [16954519.001]
  • [Cites] J Thorac Oncol. 2007 Dec;2(12):1086-90 [18090579.001]
  • [Cites] Acta Radiol. 2008 Nov;49(9):991-4 [18651255.001]
  • (PMID = 20028932.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / R01 CA121210
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS474431; NLM/ PMC3676673
  •  go-up   go-down


86. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD: Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene; 2010 Feb 4;29(5):635-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found induction of SULF2 transcripts and Sulf-2 protein in human lung adenocarcinoma and squamous cell carcinoma, the two major classes of non-small-cell lung carcinomas (NSCLCs).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):733-7 [17320573.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Nature. 2007 Apr 26;446(7139):1030-7 [17460664.001]
  • [Cites] PLoS One. 2007;2(4):e392 [17460759.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7860-72 [10630639.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1997-2005 [10854222.001]
  • [Cites] Annu Rev Biochem. 1999;68:729-77 [10872465.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):329-32 [10888884.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):316-21 [11170292.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 21;1471(3):M99-108 [11250066.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):169-73 [11457867.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):357-61 [11489926.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1663-6 [11533491.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10982-6 [11790764.001]
  • [Cites] Oncogene. 2002 Oct 21;21(48):7421-34 [12379883.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):341-51 [12860968.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7218-21 [14562050.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):231-48 [14699503.001]
  • [Cites] Int J Cancer. 2004 Mar10;109(1):106-11 [14735475.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5604-11 [14645250.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4833-8 [15051888.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207(2):197-203 [15072829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7 [15067127.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11334-7 [15273287.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6170-4 [15208662.001]
  • [Cites] Glycoconj J. 2004;21(1-2):47-52 [15467398.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2615-21 [8168088.001]
  • [Cites] J Biol Chem. 1998 Feb 20;273(8):4350-9 [9468484.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):497-506 [15542433.001]
  • [Cites] Tumour Biol. 2004 Jul-Aug;25(4):161-71 [15557753.001]
  • [Cites] Mol Cancer. 2005;4(1):14 [15817123.001]
  • [Cites] BMC Cancer. 2005;5:53 [15913453.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6245-54 [16024626.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):526-42 [16069816.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):40066-73 [16192265.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):1001-10 [16331886.001]
  • [Cites] BMC Biochem. 2006;7:2 [16417632.001]
  • [Cites] J Biol Chem. 2007 May 25;282(21):15578-88 [17405882.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5371-9 [17545618.001]
  • [Cites] PLoS One. 2007;2(6):e575 [17593974.001]
  • [Cites] Curr Pharm Des. 2007;13(20):2057-73 [17627539.001]
  • [Cites] Development. 2007 Sep;134(18):3327-38 [17720696.001]
  • [Cites] Dev Biol. 2007 Nov 15;311(2):464-77 [17920055.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):203-9 [18097596.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):89-99 [18064304.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R63 [17897439.001]
  • [Cites] Dev Dyn. 2008 Feb;237(2):339-53 [18213582.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1211-22 [18318435.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):387-98 [18432252.001]
  • [Cites] Dev Biol. 2008 Aug 15;320(2):436-45 [18617162.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6969-77 [18757411.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27724-35 [18687675.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(17):2680-8 [18790633.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R87 [18928525.001]
  • [Cites] J Biol Chem. 2009 Aug 7;284(32):21505-14 [19520866.001]
  • [Cites] J Neurosci. 2006 May 10;26(19):5037-48 [16687495.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):26943-50 [16835228.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):678-88 [17116694.001]
  • [Cites] PLoS One. 2006;1:e93 [17183725.001]
  • (PMID = 19855436.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075602; United States / NCI NIH HHS / CA / R01 CA125030-01A2; United States / NIAID NIH HHS / AI / P01 AI053194; United States / NCI NIH HHS / CA / R21 CA122025; United States / NCI NIH HHS / CA / R01 CA125030; United States / NCI NIH HHS / CA / CA125030-01A2; United States / NCI NIH HHS / CA / R01CA125030
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Wnt Proteins; EC 2.8.2.- / SULF2 protein, human; EC 2.8.2.- / Sulfotransferases
  • [Other-IDs] NLM/ NIHMS141344; NLM/ PMC2818095
  •  go-up   go-down


87. Schwartz AM, Man YG, Rezaei MK, Simmens SJ, Berg PE: BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia. Mod Pathol; 2009 Jan;22(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.
  • Significant mRNA expression and immunohistochemical reactivity of BP1 is present in a majority of breast cancers and in all cases of inflammatory breast cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Homeodomain Proteins / biosynthesis. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931648.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DLX4 protein, human; 0 / Homeodomain Proteins; 0 / Transcription Factors; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


88. Rodriguez-Collazo P, Snyder SK, Chiffer RC, Zlatanova J, Leuba SH, Smith CL: cAMP signaling induces rapid loss of histone H3 phosphorylation in mammary adenocarcinoma-derived cell lines. Exp Cell Res; 2008 Jan 1;314(1):1-10
PDF icon [Fulltext service] Download